Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Site ID- Subject ID- Patient ID	Country Gender Age	Treatment Start Date/ End Date
[redacted]	NLD M 6[redacted]	[redacted]20[redacted]/ [redacted]20[redacted]
[redacted]	GBR M 5[redacted]	[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]

Dose leve=0.38 mg - ESCALATION

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=0.76 mg - ESCALATION

Site ID- Subject ID- Patient ID	Country Gender Age	Sponsor ID	AE Term	Body System or Organ Class	Dictionary-Derived Term	AE Start Date/ Day	AE End Date/ Day	Treatment Emergent Analysis Flag	Analysis Causality	Grade
[redacted]	DNK M 2[redacted]	11	PROGRESSION DISEASE DUE TO LYMPHOMA	良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	悪性新生物進行	[redacted]20[redacted] -/ 83	[redacted]20[redacted] -/ 83		NOT RELATED	5
		2	SEIZURE	神経系障害	痙攣発作	[redacted]20[redacted] 12:00/ 5	[redacted]20[redacted] 12:02/ 5	Y	NOT RELATED	2
[redacted]	DNK M 5[redacted]	9	ALKALINE PHOSPHATATE INCREASED	臨床検査	血中アルカリホスファターゼ増加	[redacted]20[redacted] -/ 37	[redacted]20[redacted] -/ 79	Y	NOT RELATED	3
[redacted]	NLD M 6[redacted]	8	EUTHANASIA	外科および内科処置	安楽死	[redacted]20[redacted] -/ 44	[redacted]20[redacted] -/ 44	Y	NOT RELATED	5
[redacted]	NLD M 5[redacted]	12	WORSENING PLEURAL EFFUSION	呼吸器、胸郭および縦隔障害	胸水	[redacted]20[redacted] -/ 16		Y	NOT RELATED	3
		16	DISEASE PROGRESSION	良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	悪性新生物進行	[redacted]20[redacted] -/ 49	[redacted]20[redacted] -/ 49	Y	NOT RELATED	5

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=0.76 mg - ESCALATION

Site ID- Subject ID- Patient ID	Country Gender Age	Analysis Acn Taken with Study Trt	Outcome of Adverse Event	Grade 1 Change/ Date Time	Grade 2 Change/ Date Time	Grade 3 Change/ Date Time	Grade 4 Change/ Date Time	Grade 5 Change/ Date Time	Grade 6 Change/ Date Time	Grade 7 Change/ Date Time	Grade 8 Change/ Date Time	Grade 9 Change/ Date Time
[redacted]	DNK M 2[redacted]	NOT APPLICABLE	FATAL	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
[redacted]	DNK M 5[redacted]	DOSE NOT CHANGED	RECOVERED/ RESOLVED	3/ [redacted]20[redacted]	2/ [redacted]20[redacted]	-	-	-	-	-	-	-
[redacted]	NLD M 6[redacted]	NOT APPLICABLE	FATAL	-	-	-	-	-	-	-	-	-
[redacted]	NLD M 5[redacted]	DOSE NOT CHANGED	UNKNOWN	3/ [redacted]20[redacted]	2/ [redacted]20[redacted]	-	-	-	-	-	-	-
		NOT APPLICABLE	FATAL	-	-	-	-	-	-	-	-	-

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Site ID- Subject ID- Patient ID	Country Gender Age	Treatment Start Date/ End Date
Dose leve=0.76 mg - ESCALATION		
[redacted]	DNK M 2[redacted]	[redacted]20[redacted]/ 20[redacted]
		[redacted]20[redacted]/ 20[redacted]
[redacted]	DNK M 5[redacted]	[redacted]20[redacted]/ 20[redacted]
[redacted]	NLD M 6[redacted]	[redacted]20[redacted]/ 20[redacted]
[redacted]	NLD M 5[redacted]	[redacted]20[redacted]/ 20[redacted]
		[redacted]20[redacted]/ 20[redacted]

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=0.76 mg - ESCALATION

Site ID- Subject ID- Patient ID	Country Gender Age	Sponsor ID	AE Term	Body System or Organ Class	Dictionary-Derived Term	AE Start Date/ Day	AE End Date/ Day	Treatment Emergent Analysis Flag	Analysis Causality	Grade
[redacted]	NLD M 5[redacted]	18	WORSENING PLEURAL EFFUSION	呼吸器、胸郭および縦隔障害	胸水	[redacted]20[redacted] -/ 4	[redacted]20[redacted] -/ 15	Y	NOT RELATED	3
		2	WORSENING DYSPNEA	呼吸器、胸郭および縦隔障害	呼吸困難	[redacted]20[redacted] -/ 2		Y	NOT RELATED	4
[redacted]	GBR F 5[redacted]	1	NEUROLOGICAL SYMPTOMS	神経系障害	神経学的症状	[redacted]20[redacted] -/ 135	[redacted]20[redacted] -/ 137	Y	RELATED	1
		6	SEIZURE	神経系障害	痙攣発作	[redacted]20[redacted] -/ 135	[redacted]20[redacted] -/ 137	Y	RELATED	1

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=0.76 mg - ESCALATION

Site ID- Subject ID- Patient ID	Country Gender Age	Analysis Acn Taken with Study Trt	Outcome of Adverse Event	Grade 1 Change/ Date Time	Grade 2 Change/ Date Time	Grade 3 Change/ Date Time	Grade 4 Change/ Date Time	Grade 5 Change/ Date Time	Grade 6 Change/ Date Time	Grade 7 Change/ Date Time	Grade 8 Change/ Date Time	Grade 9 Change/ Date Time
[redacted]	NLD M 5[redacted]	DOSE NOT CHANGED	RECOVERED/ RESOLVED	1/ [redacted]20[redacted]	-	-	-	-	-	-	-	-
		DRUG WITHDRAWN	NOT RECOVERED/ NOT RESOLVED	4/ [redacted]20[redacted]	-	-	-	-	-	-	-	-
[redacted]	GBR F 5[redacted]	DRUG INTERRUPTED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DRUG INTERRUPTED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=0.76 mg - ESCALATION		
Site ID- Subject ID- Patient ID	Country Gender Age	Treatment Start Date/ End Date
[redacted]	NLD M 5[redacted]	[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
[redacted]	GBR F 5[redacted]	[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=1.5 mg - ESCALATION

Site ID- Subject ID- Patient ID	Country Gender Age	Sponsor ID	AE Term	Body System or Organ Class	Dictionary-Derived Term	AE Start Date/ Day	AE End Date/ Day	Treatment Emergent Analysis Flag	Analysis Causality	Grade
[redacted]	DNK M 4[redacted]	1	CYTOKINE RELEASE SYNDROME	免疫系障害	サイトカイン放出症候群	[redacted]20[redacted] 06:10/ 30	[redacted]20[redacted] 09:41/ 32	Y	RELATED	1
		2	CYTOKINE RELEASE SYNDROME	免疫系障害	サイトカイン放出症候群	[redacted]20[redacted] 07:45/ 33	[redacted]20[redacted] 23:59/ 34	Y	RELATED	1
		3	CYTOKINE RELEASE SYNDROME	免疫系障害	サイトカイン放出症候群	[redacted]20[redacted] 21:42/ 38	[redacted]20[redacted] 11:05/ 39	Y	RELATED	1
		19	FEVER	一般・全身障害および投与部位の状態	発熱	[redacted]20[redacted] 10:55/ 30	[redacted]20[redacted] 10:55/ 31	Y	RELATED	3
		20	FEVER	一般・全身障害および投与部位の状態	発熱	[redacted]20[redacted] 07:45/ 33	[redacted]20[redacted] 00:20/ 34	Y	RELATED	3
		22	FEVER	一般・全身障害および投与部位の状態	発熱	[redacted]20[redacted] 19:44/ 38	[redacted]20[redacted] 06:50/ 39	Y	RELATED	3

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=1.5 mg - ESCALATION

Site ID- Subject ID- Patient ID	Country Gender Age	Analysis Acn Taken with Study Trt	Outcome of Adverse Event	Grade 1 Change/ Date Time	Grade 2 Change/ Date Time	Grade 3 Change/ Date Time	Grade 4 Change/ Date Time	Grade 5 Change/ Date Time	Grade 6 Change/ Date Time	Grade 7 Change/ Date Time	Grade 8 Change/ Date Time	Grade 9 Change/ Date Time
[redacted]	DNK M 4[redacted]	DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	2/ [redacted] 22:08	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	1/ [redacted] 20:30	-	-	-	-	-	-	-	-

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Site ID- Subject ID- Patient ID	Country Gender Age	Treatment Start Date/ End Date
[redacted]	DNK M 4[redacted]	[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]

Dose leve=1.5 mg - ESCALATION

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=1.5 mg - ESCALATION

Site ID- Subject ID- Patient ID	Country Gender Age	Sponsor ID	AE Term	Body System or Organ Class	Dictionary-Derived Term	AE Start Date/ Day	AE End Date/ Day	Treatment Emergent Analysis Flag	Analysis Causality	Grade
[redacted]	DNK M 4[redacted]	28	WOUND INFEKTION IN SCALP.	感染症および寄生虫症	創傷感染	[redacted]20[redacted] -/ 68		Y	NOT RELATED	3
		29	DISEASE PROGRESSION	良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	悪性新生物進行	[redacted]20[redacted] -/ 77	[redacted]20[redacted] -/ 77		NOT RELATED	5
		8	FATIGUE	一般・全身障害および投与部位の状態	疲労	[redacted]20[redacted] 12:00/ -5		Y	NOT RELATED	3
[redacted]	NLD M 7[redacted]	8	DISEASE PROGRESSION	良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	悪性新生物進行	[redacted]20[redacted] -/ 81	[redacted]20[redacted] -/ 81		NOT RELATED	5
[redacted]	GBR M 6[redacted]	1	LUNG INFECTION	感染症および寄生虫症	肺炎	[redacted]20[redacted] -/ 14	[redacted]20[redacted] -/ 26	Y	NOT RELATED	3
		7	DISEASE PROGRESSION	良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	悪性新生物進行	[redacted]20[redacted] -/ 45	[redacted]20[redacted] -/ 45		NOT RELATED	5

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=1.5 mg - ESCALATION

Site ID- Subject ID- Patient ID	Country Gender Age	Analysis Acn Taken with Study Trt	Outcome of Adverse Event	Grade 1 Change/ Date Time	Grade 2 Change/ Date Time	Grade 3 Change/ Date Time	Grade 4 Change/ Date Time	Grade 5 Change/ Date Time	Grade 6 Change/ Date Time	Grade 7 Change/ Date Time	Grade 8 Change/ Date Time	Grade 9 Change/ Date Time
[redacted]	DNK M 4[redacted]	NOT APPLICABLE	NOT RECOVERED/ NOT RESOLVED	-	-	-	-	-	-	-	-	-
		NOT APPLICABLE	FATAL	-	-	-	-	-	-	-	-	-
		NOT APPLICABLE	NOT RECOVERED/ NOT RESOLVED	3/[redacted]20[redacted]	-	-	-	-	-	-	-	-
[redacted]	NLD M 7[redacted]	NOT APPLICABLE	FATAL	-	-	-	-	-	-	-	-	-
[redacted]	GBR M 6[redacted]	DRUG WITHDRAWN	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		NOT APPLICABLE	FATAL	-	-	-	-	-	-	-	-	-

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Site ID- Subject ID- Patient ID	Country Gender Age	Treatment Start Date/ End Date
[redacted]	DNK M 4[redacted]	[redacted]20[redacted]/ 20[redacted]
		[redacted]20[redacted]/ 20[redacted]
		[redacted]20[redacted]/ 20[redacted]
[redacted]	NLD M 7[redacted]	[redacted]20[redacted]/ 20[redacted]
[redacted]	GBR M 6[redacted]	[redacted]20[redacted]/ 20[redacted]
		[redacted]20[redacted]/ 20[redacted]

Dose leve=1.5 mg - ESCALATION

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=1.5 mg - ESCALATION

Site ID-Subject ID-Patient ID	Country Gender Age	Sponsor ID	AE Term	Body System or Organ Class	Dictionary-Derived Term	AE Start Date/Day	AE End Date/Day	Treatment Emergent Analysis Flag	Analysis Causality	Grade
[redacted]	GBR M 7[redacted]	1	SKIN INFECTION LEFT AXILLARY SINUS	感染症および寄生虫症	皮膚感染	[redacted]20[redacted] -/ 7	[redacted]20[redacted] -/ 119	Y	NOT RELATED	3
		16	DISEASE PROGRESSION	良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	悪性新生物進行	[redacted]20[redacted] -/ 114	[redacted]20[redacted] -/ 119		NOT RELATED	5
[redacted]	GBR M 5[redacted]	18	PROGRESSIVE DISEASE	良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	悪性新生物進行	[redacted]20[redacted] -/ 144	[redacted]20[redacted] -/ 144		NOT RELATED	5
		2	LEFT GROIN PAIN	筋骨格系および結合組織障害	鼠径部痛	[redacted]20[redacted] -/ 15		Y	NOT RELATED	3
		5	COLITIS, INFECTIOUS (CLOSTRIDIUM DIFFICILE)	感染症および寄生虫症	クロストリジウム・ディフィシレ大腸炎	[redacted]20[redacted] -/ 25	[redacted]20[redacted] -/ 39	Y	NOT RELATED	2

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=1.5 mg - ESCALATION

Site ID-Subject ID-Patient ID	Country Gender Age	Analysis Acn Taken with Study Trt	Outcome of Adverse Event	Grade 1 Change/ Date Time	Grade 2 Change/ Date Time	Grade 3 Change/ Date Time	Grade 4 Change/ Date Time	Grade 5 Change/ Date Time	Grade 6 Change/ Date Time	Grade 7 Change/ Date Time	Grade 8 Change/ Date Time	Grade 9 Change/ Date Time
[redacted]	GBR M 7[redacted]	DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		NOT APPLICABLE	FATAL	-	-	-	-	-	-	-	-	-
[redacted]	GBR M 5[redacted]	NOT APPLICABLE	FATAL	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	NOT RECOVERED/ NOT RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Site ID- Subject ID- Patient ID	Country Gender Age	Treatment Start Date/ End Date
Dose leve=1.5 mg - ESCALATION		
[redacted]	GBR M 7[redacted]	[redacted]20[redacted]/ 20[redacted]
		[redacted]20[redacted]/ 20[redacted]
[redacted]	GBR M 5[redacted]	[redacted]20[redacted]/ 20[redacted]
		[redacted]20[redacted]/ 20[redacted]
		[redacted]20[redacted]/ 20[redacted]

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=3 mg - ESCALATION

Site ID- Subject ID- Patient ID	Country Gender Age	Sponsor ID	AE Term	Body System or Organ Class	Dictionary-Derived Term	AE Start Date/ Day	AE End Date/ Day	Treatment Emergent Analysis Flag	Analysis Causality	Grade
[redacted]	GBR M 3[redacted]	2	RHINOVIRUS INFECTION	感染症および寄生虫症	ライノウイルス感染	[redacted]20[redacted] -/ 19	[redacted]20[redacted] -/ 22	Y	NOT RELATED	3
		3	RHINOVIRUS	感染症および寄生虫症	ライノウイルス感染	[redacted]20[redacted] -/ 34	[redacted]20[redacted] -/ 37	Y	NOT RELATED	3
[redacted]	GBR F 6[redacted]	18	WORSENING OF BACK PAIN	筋骨格系および結合組織障害	背部痛	[redacted]20[redacted] -/ 224		Y	NOT RELATED	2
		4	LUNG INFECTION	感染症および寄生虫症	肺炎	[redacted]20[redacted] -/ 15	[redacted]20[redacted] -/ 22	Y	NOT RELATED	3
		5	LYMPHODEMA LEFT BREAST	血管障害	リンパ浮腫	[redacted]20[redacted] -/ 11	[redacted]20[redacted] -/ 43	Y	NOT RELATED	2
		6	LUNG INFECTION	感染症および寄生虫症	肺炎	[redacted]20[redacted] -/ 29	[redacted]20[redacted] -/ 38	Y	NOT RELATED	2

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=3 mg - ESCALATION

Site ID-Subject ID-Patient ID	Country Gender Age	Analysis Acn Taken with Study Trt	Outcome of Adverse Event	Grade 1 Change/ Date Time	Grade 2 Change/ Date Time	Grade 3 Change/ Date Time	Grade 4 Change/ Date Time	Grade 5 Change/ Date Time	Grade 6 Change/ Date Time	Grade 7 Change/ Date Time	Grade 8 Change/ Date Time	Grade 9 Change/ Date Time
[redacted]	GBR M 3[redacted]	DRUG INTERRUPTED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DRUG INTERRUPTED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
[redacted]	GBR F 6[redacted]	DRUG INTERRUPTED	NOT RECOVERED/ NOT RESOLVED	-	-	-	-	-	-	-	-	-
		DRUG INTERRUPTED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Site ID- Subject ID- Patient ID	Country Gender Age	Treatment Start Date/ End Date
[redacted]	GBR M 3[redacted]	[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
[redacted]	GBR F 6[redacted]	[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=3 mg - ESCALATION

Site ID-Subject ID-Patient ID	Country Gender Age	Sponsor ID	AE Term	Body System or Organ Class	Dictionary-Derived Term	AE Start Date/Day	AE End Date/Day	Treatment Emergent Analysis Flag	Analysis Causality	Grade
[redacted]	GBR M 7[redacted]	11	ACUTE CORONARY SYNDROME	心臓障害	急性冠動脈症候群	[redacted]20[redacted] -/ 22	[redacted]20[redacted] -/ 22	Y	NOT RELATED	3
		12	SEVERE CORONARY ARTERY DISEASE	心臓障害	冠動脈疾患	[redacted]20[redacted] -/ 26		Y	NOT RELATED	3
		14	PSEUDOMONAS AERUGINOSA	感染症および寄生虫症	シュードモナス感染	[redacted]20[redacted] -/ 76	[redacted]20[redacted] -/ 94	Y	NOT RELATED	3
		15	INTERMITTENT CHEST PAIN (MUSCULOSKELETAL)	筋骨格系および結合組織障害	筋骨格系胸痛	[redacted]20[redacted] -/ 31	[redacted]20[redacted] -/ 70	Y	NOT RELATED	2
		17	UPPER RESPIRATORY TRACT INFECTION	感染症および寄生虫症	上気道感染	[redacted]20[redacted] -/ 109	[redacted]20[redacted] -/ 115	Y	NOT RELATED	2
		20	DISEASE PROGRESSION	良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	悪性新生物進行	[redacted]20[redacted] -/ 129	[redacted]20[redacted] -/ 163	Y	NOT RELATED	5

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=3 mg - ESCALATION

Site ID-Subject ID-Patient ID	Country Gender Age	Analysis Acn Taken with Study Trt	Outcome of Adverse Event	Grade 1 Change/ Date Time	Grade 2 Change/ Date Time	Grade 3 Change/ Date Time	Grade 4 Change/ Date Time	Grade 5 Change/ Date Time	Grade 6 Change/ Date Time	Grade 7 Change/ Date Time	Grade 8 Change/ Date Time	Grade 9 Change/ Date Time
[redacted]	GBR M 7[redacted]	DRUG INTERRUPTED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DRUG INTERRUPTED	NOT RECOVERED/ NOT RESOLVED	-	-	-	-	-	-	-	-	-
		DRUG INTERRUPTED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		NOT APPLICABLE	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DRUG WITHDRAWN	FATAL	-	-	-	-	-	-	-	-	-

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=3 mg - ESCALATION		
Site ID- Subject ID- Patient ID	Country Gender Age	Treatment Start Date/ End Date
[redacted]	GBR M 7[redacted]	[redacted]20[redacted]/ 20[redacted]
		[redacted]20[redacted]/ 20[redacted]
		[redacted]20[redacted]/ 20[redacted]
		[redacted]20[redacted]/ 20[redacted]
		[redacted]20[redacted]/ 20[redacted]
		[redacted]20[redacted]/ 20[redacted]

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=3 mg - ESCALATION

Site ID- Subject ID- Patient ID	Country Gender Age	Sponsor ID	AE Term	Body System or Organ Class	Dictionary-Derived Term	AE Start Date/ Day	AE End Date/ Day	Treatment Emergent Analysis Flag	Analysis Causality	Grade
[redacted]	GBR M 7[redacted]	22	PLEURAL EFFUSIONS	呼吸器、胸郭および縦隔障害	胸水	[redacted]20[redacted] -/ 126		Y	NOT RELATED	2
[redacted]	GBR M 7[redacted]	2	CYTOKINE RELEASE SYNDROME	免疫系障害	サイトカイン放出症候群	[redacted]20[redacted] 12:35/ 25	[redacted]20[redacted] -/ 30	Y	RELATED	2
		11	PROGRESSIVE DISEASE	良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	悪性新生物進行	[redacted]20[redacted] -/ 29	[redacted]20[redacted] -/ 87	Y	NOT RELATED	5
		9	INTERMITTENT FEVERS	一般・全身障害および投与部位の状態	発熱	[redacted]20[redacted] 12:35/ 25	[redacted]20[redacted] 11:25/ 30	Y	RELATED	1

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=3 mg - ESCALATION

Site ID- Subject ID- Patient ID	Country Gender Age	Analysis Acn Taken with Study Trt	Outcome of Adverse Event	Grade 1 Change/ Date Time	Grade 2 Change/ Date Time	Grade 3 Change/ Date Time	Grade 4 Change/ Date Time	Grade 5 Change/ Date Time	Grade 6 Change/ Date Time	Grade 7 Change/ Date Time	Grade 8 Change/ Date Time	Grade 9 Change/ Date Time
[redacted]	GBR M 7[redacted]	DOSE NOT CHANGED	NOT RECOVERED/ NOT RESOLVED	1/[redacted]20[redacted]	-	-	-	-	-	-	-	-
[redacted]	GBR M 7[redacted]	DRUG INTERRUPTED	RECOVERED/ RESOLVED	1/[redacted]20[redacted]	-	-	-	-	-	-	-	-
		NOT APPLICABLE	FATAL	-	-	-	-	-	-	-	-	-
		DRUG INTERRUPTED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Site ID- Subject ID- Patient ID	Country Gender Age	Treatment Start Date/ End Date
[redacted]	GBR M 7[redacted]	[redacted]20[redacted]/ 20[redacted]
[redacted]	GBR M 7[redacted]	[redacted]20[redacted]/ 20[redacted]
		[redacted]20[redacted]/ 20[redacted]
		[redacted]20[redacted]/ 20[redacted]

Dose leve=3 mg - ESCALATION

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=6 mg - ESCALATION

Site ID-Subject ID-Patient ID	Country Gender Age	Sponsor ID	AE Term	Body System or Organ Class	Dictionary-Derived Term	AE Start Date/Day	AE End Date/Day	Treatment Emergent Analysis Flag	Analysis Causality	Grade
[redacted]	DNK M 7[redacted]	1	CYTOKINE RELEASE SYNDROME	免疫系障害	サイトカイン放出症候群	[redacted]20[redacted] 09:19/ 12	[redacted]20[redacted] 13:46/ 12	Y	RELATED	1
		2	CYTOKINE RELEASE SYNDROME	免疫系障害	サイトカイン放出症候群	[redacted]20[redacted] -/ 19	[redacted]20[redacted] 10:42/ 20	Y	RELATED	1
		3	CYTOKINE RELEASE SYNDROME	免疫系障害	サイトカイン放出症候群	[redacted]20[redacted] 02:45/ 25	[redacted]20[redacted] 15:16/ 26	Y	RELATED	1
		1	TACHYCARDIA	心臓障害	頻脈	[redacted]20[redacted] 13:30/ 4	[redacted]20[redacted] 06:15/ 5	Y	NOT RELATED	1
		11	HEADACHE	神経系障害	頭痛	[redacted]20[redacted] 09:19/ 12	[redacted]20[redacted] 13:46/ 12	Y	RELATED	1
		12	DIZZINESS	神経系障害	浮動性めまい	[redacted]20[redacted] 09:19/ 12	[redacted]20[redacted] 13:46/ 12	Y	RELATED	1

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=6 mg - ESCALATION

Site ID-Subject ID-Patient ID	Country Gender Age	Analysis Acn Taken with Study Trt	Outcome of Adverse Event	Grade 1 Change/ Date Time	Grade 2 Change/ Date Time	Grade 3 Change/ Date Time	Grade 4 Change/ Date Time	Grade 5 Change/ Date Time	Grade 6 Change/ Date Time	Grade 7 Change/ Date Time	Grade 8 Change/ Date Time	Grade 9 Change/ Date Time
[redacted]	DNK M 7[redacted]	DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Site ID- Subject ID- Patient ID	Country Gender Age	Treatment Start Date/ End Date
[redacted]	DNK M 7[redacted]	[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]

Dose leve=6 mg - ESCALATION

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=6 mg - ESCALATION

Site ID- Subject ID- Patient ID	Country Gender Age	Sponsor ID	AE Term	Body System or Organ Class	Dictionary-Derived Term	AE Start Date/ Day	AE End Date/ Day	Treatment Emergent Analysis Flag	Analysis Causality	Grade
[redacted]	DNK M 7[redacted]	13	CHEST PAIN	一般・全身障害および投与部位の状態	胸痛	[redacted]20[redacted] -/ 19	[redacted]20[redacted] 10:41/ 19	Y	RELATED	1
		14	ABDOMINAL PAIN	胃腸障害	腹痛	[redacted]20[redacted] -/ 19	[redacted]20[redacted] 10:41/ 19	Y	RELATED	1
		15	SWEATS	皮膚および皮下組織障害	多汗症	[redacted]20[redacted] -/ 19	[redacted]20[redacted] 10:42/ 20	Y	RELATED	1
		16	SHIVERING	一般・全身障害および投与部位の状態	悪寒	[redacted]20[redacted] -/ 19	[redacted]20[redacted] 10:42/ 20	Y	RELATED	1
		17	FEVER	一般・全身障害および投与部位の状態	発熱	[redacted]20[redacted] -/ 19	[redacted]20[redacted] 06:30/ 20	Y	RELATED	1
		21	HEADACHE	神経系障害	頭痛	[redacted]20[redacted] 02:45/ 25	[redacted]20[redacted] 15:16/ 26	Y	RELATED	1

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=6 mg - ESCALATION

Site ID- Subject ID- Patient ID	Country Gender Age	Analysis Acn Taken with Study Trt	Outcome of Adverse Event	Grade 1 Change/ Date Time	Grade 2 Change/ Date Time	Grade 3 Change/ Date Time	Grade 4 Change/ Date Time	Grade 5 Change/ Date Time	Grade 6 Change/ Date Time	Grade 7 Change/ Date Time	Grade 8 Change/ Date Time	Grade 9 Change/ Date Time
[redacted]	DNK M 7[redacted]	DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Site ID- Subject ID- Patient ID	Country Gender Age	Treatment Start Date/ End Date
[redacted]	DNK M 7[redacted]	[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]

Dose leve=6 mg - ESCALATION

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=6 mg - ESCALATION

Site ID- Subject ID- Patient ID	Country Gender Age	Sponsor ID	AE Term	Body System or Organ Class	Dictionary-Derived Term	AE Start Date/ Day	AE End Date/ Day	Treatment Emergent Analysis Flag	Analysis Causality	Grade
[redacted]	DNK M 7[redacted]	22	FEVER	一般・全身障害および投与部位の状態	発熱	[redacted]20[redacted] 02:45/ 25	[redacted]20[redacted] 15:16/ 26	Y	RELATED	2
		23	DYSPNEA	呼吸器、胸郭および縦隔障害	呼吸困難	[redacted]20[redacted] 02:45/ 25	[redacted]20[redacted] 15:16/ 26	Y	RELATED	1
		7	FEVER	一般・全身障害および投与部位の状態	発熱	[redacted]20[redacted] 09:19/ 12	[redacted]20[redacted] 13:46/ 12	Y	RELATED	1
[redacted]	DNK M 8[redacted]	20	PNEUMONIA	感染症および寄生虫症	肺炎	[redacted]20[redacted] -/ 121	[redacted]20[redacted] 14:04/ 140	Y	NOT RELATED	3
[redacted]	DNK M 5[redacted]	1	HYPOPHOSPHATEMIA	代謝および栄養障害	低リン血症	[redacted]20[redacted] 12:55/ -5	[redacted]20[redacted] 08:56/ 1		NOT RELATED	4
		6	DISEASE PROGRESSION	良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	悪性新生物進行	[redacted]20[redacted] 07:30/ 7	[redacted]20[redacted] 07:30/ 7	Y	NOT RELATED	5

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=6 mg - ESCALATION

Site ID- Subject ID- Patient ID	Country Gender Age	Analysis Acn Taken with Study Trt	Outcome of Adverse Event	Grade 1 Change/ Date Time	Grade 2 Change/ Date Time	Grade 3 Change/ Date Time	Grade 4 Change/ Date Time	Grade 5 Change/ Date Time	Grade 6 Change/ Date Time	Grade 7 Change/ Date Time	Grade 8 Change/ Date Time	Grade 9 Change/ Date Time
[redacted]	DNK M 7[redacted]	DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
[redacted]	DNK M 8[redacted]	NOT APPLICABLE	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
[redacted]	DNK M 5[redacted]	NOT APPLICABLE	RECOVERED/ RESOLVED	2/[redacted]20[redacted] 02:50	-	-	-	-	-	-	-	-
		DRUG WITHDRAWN	FATAL	-	-	-	-	-	-	-	-	-

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=6 mg - ESCALATION		
Site ID- Subject ID- Patient ID	Country Gender Age	Treatment Start Date/ End Date
[redacted]	DNK M 7[redacted]	[redacted]20[redacted]/ 20[redacted]
		[redacted]20[redacted]/ 20[redacted]
		[redacted]20[redacted]/ 20[redacted]
[redacted]	DNK M 8[redacted]	[redacted]20[redacted]/ 20[redacted]
[redacted]	DNK M 5[redacted]	[redacted]20[redacted]/ 20[redacted]
		[redacted]20[redacted]/ 20[redacted]

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=6 mg - ESCALATION

Site ID- Subject ID- Patient ID	Country Gender Age	Sponsor ID	AE Term	Body System or Organ Class	Dictionary-Derived Term	AE Start Date/ Day	AE End Date/ Day	Treatment Emergent Analysis Flag	Analysis Causality	Grade
[redacted]	DNK M 7[redacted]	1	CYTOKINE RELEASE SYNDROME	免疫系障害	サイトカイン放出症候群	[redacted]20[redacted] 21:50/ 11	[redacted]20[redacted] 18:23/ 12	Y	RELATED	1
		2	CYTOKINE RELEASE SYNDROME	免疫系障害	サイトカイン放出症候群	[redacted]20[redacted] 15:19/ 21	[redacted]20[redacted] -/ 22	Y	RELATED	1
		3	FEVER (CRS)	一般・全身障害および投与部位の状態	発熱	[redacted]20[redacted] 21:50/ 11	[redacted]20[redacted] 18:23/ 12	Y	RELATED	2
		5	FEVER (CRS)	一般・全身障害および投与部位の状態	発熱	[redacted]20[redacted] 15:19/ 21	[redacted]20[redacted] -/ 22	Y	RELATED	1
[redacted]	DNK F 7[redacted]	17	SPINAL CORD COMPRESSION	神経系障害	脊髄圧迫	[redacted]20[redacted] -/ -3	[redacted]20[redacted] -/ -2		NOT RELATED	3
[redacted]	NLD M 7[redacted]	3	CYTOKINE RELEASE SYNDROME	免疫系障害	サイトカイン放出症候群	[redacted]20[redacted] -/ 18	[redacted]20[redacted] -/ 23	Y	RELATED	1

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=6 mg - ESCALATION

Site ID- Subject ID- Patient ID	Country Gender Age	Analysis Acn Taken with Study Trt	Outcome of Adverse Event	Grade 1 Change/ Date Time	Grade 2 Change/ Date Time	Grade 3 Change/ Date Time	Grade 4 Change/ Date Time	Grade 5 Change/ Date Time	Grade 6 Change/ Date Time	Grade 7 Change/ Date Time	Grade 8 Change/ Date Time	Grade 9 Change/ Date Time
[redacted]	DNK M 7[redacted]	DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
[redacted]	DNK F 7[redacted]	NOT APPLICABLE	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
[redacted]	NLD M 7[redacted]	DRUG INTERRUPTE D	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Site ID- Subject ID- Patient ID	Country Gender Age	Treatment Start Date/ End Date
Dose leve=6 mg - ESCALATION		
[redacted]	DNK M 7[redacted]	[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
[redacted]	DNK F 7[redacted]	[redacted]20[redacted]/ [redacted]20[redacted]
[redacted]	NLD M 7[redacted]	[redacted]20[redacted]/ [redacted]20[redacted]

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=6 mg - ESCALATION

Site ID- Subject ID- Patient ID	Country Gender Age	Sponsor ID	AE Term	Body System or Organ Class	Dictionary-Derived Term	AE Start Date/ Day	AE End Date/ Day	Treatment Emergent Analysis Flag	Analysis Causality	Grade
[redacted]	NLD M 7[redacted]	16	FEVER	一般・全身障害および投与部位の状態	発熱	[redacted]20[redacted] -/ 18	[redacted]20[redacted] 10:41/ 20	Y	RELATED	2
		25	DYSPNEA	呼吸器、胸郭および縦隔障害	呼吸困難	[redacted]20[redacted] -/ 26		Y	NOT RELATED	2
		27	DISEASE PROGRESSION	良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	悪性新生物進行	[redacted]20[redacted] -/ 63	[redacted]20[redacted] -/ 63		NOT RELATED	5
[redacted]	GBR F 7[redacted]	1	LUNG INFECTION	感染症および寄生虫症	肺炎	[redacted]20[redacted] -/ 17	[redacted]20[redacted] -/ 21	Y	NOT RELATED	3
		10	FEVER	一般・全身障害および投与部位の状態	発熱	[redacted]20[redacted] -/ 133	[redacted]20[redacted] -/ 134	Y	NOT RELATED	1
		11	LOCALISED RASH	皮膚および皮下組織障害	発疹	[redacted]20[redacted] -/ 133	[redacted]20[redacted] -/ 134	Y	NOT RELATED	1

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=6 mg - ESCALATION

Site ID- Subject ID- Patient ID	Country Gender Age	Analysis Acn Taken with Study Trt	Outcome of Adverse Event	Grade 1 Change/ Date Time	Grade 2 Change/ Date Time	Grade 3 Change/ Date Time	Grade 4 Change/ Date Time	Grade 5 Change/ Date Time	Grade 6 Change/ Date Time	Grade 7 Change/ Date Time	Grade 8 Change/ Date Time	Grade 9 Change/ Date Time
[redacted]	NLD M 7[redacted]	DRUG INTERRUPTE D	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DRUG INTERRUPTE D	NOT RECOVERED/ NOT RESOLVED	1/ [redacted]20[redacted]	-	-	-	-	-	-	-	-
		NOT APPLICABLE	FATAL	-	-	-	-	-	-	-	-	-
[redacted]	GBR F 7[redacted]	DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Site ID- Subject ID- Patient ID	Country Gender Age	Treatment Start Date/ End Date
Dose leve=6 mg - ESCALATION		
[redacted]	NLD M 7[redacted]	[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
[redacted]	GBR F 7[redacted]	[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=6 mg - ESCALATION

Site ID- Subject ID- Patient ID	Country Gender Age	Sponsor ID	AE Term	Body System or Organ Class	Dictionary-Derived Term	AE Start Date/ Day	AE End Date/ Day	Treatment Emergent Analysis Flag	Analysis Causality	Grade
[redacted]	GBR F 7[redacted]	18	UPPER RESPIRATORY TRACT INFECTION	感染症および寄生虫症	上気道感染	[redacted]20[redacted] -/ 573	[redacted]20[redacted] -/ 575	Y	NOT RELATED	1
		24	RESPIRATORY TRACT INFECTION	感染症および寄生虫症	気道感染	[redacted]20[redacted] -/ 604	[redacted]20[redacted] -/ 626	Y	RELATED	3
		25	FEVER	一般・全身障害および投与部位の状態	発熱	[redacted]20[redacted] -/ 619	[redacted]20[redacted] -/ 626	Y	NOT RELATED	3
[redacted]	GBR M 6[redacted]	9	PROGRESSIVE DISEASE	良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	悪性新生物進行	[redacted]20[redacted] -/ 67	[redacted]20[redacted] -/ 67		NOT RELATED	5

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=6 mg - ESCALATION

Site ID- Subject ID- Patient ID	Country Gender Age	Analysis Acn Taken with Study Trt	Outcome of Adverse Event	Grade 1 Change/ Date Time	Grade 2 Change/ Date Time	Grade 3 Change/ Date Time	Grade 4 Change/ Date Time	Grade 5 Change/ Date Time	Grade 6 Change/ Date Time	Grade 7 Change/ Date Time	Grade 8 Change/ Date Time	Grade 9 Change/ Date Time
[redacted]	GBR F 7[redacted]	DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DRUG WITHDRAWN	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
[redacted]	GBR M 6[redacted]	NOT APPLICABLE	FATAL	-	-	-	-	-	-	-	-	-

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Site ID- Subject ID- Patient ID	Country Gender Age	Treatment Start Date/ End Date
[redacted]	GBR F 7[redacted]	[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
[redacted]	GBR M 6[redacted]	[redacted]20[redacted]/ [redacted]20[redacted]

Dose leve=6 mg - ESCALATION

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=12 mg - ESCALATION

Site ID- Subject ID- Patient ID	Country Gender Age	Sponsor ID	AE Term	Body System or Organ Class	Dictionary-Derived Term	AE Start Date/ Day	AE End Date/ Day	Treatment Emergent Analysis Flag	Analysis Causality	Grade
[redacted]	NLD F 7[redacted]	1	CYTOKINE RELEASE SYNDROME	免疫系障害	サイトカイン放出症候群	[redacted]20[redacted] 08:50/ 17	[redacted]20[redacted] -/ 19	Y	RELATED	2
		15	DISEASE PROGRESSION	良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	悪性新生物進行	[redacted]20[redacted] -/ 43	[redacted]20[redacted] -/ 43	Y	NOT RELATED	5
		4	FEVER	一般・全身障害および投与部位の状態	発熱	[redacted]20[redacted] 08:50/ 17	[redacted]20[redacted] 14:17/ 17	Y	RELATED	2
[redacted]	GBR F 7[redacted]	1	NEUROLOGICAL SYMPTOMS	神経系障害	神経学的症状	[redacted]20[redacted] -/ 11	[redacted]20[redacted] -/ 13	Y	RELATED	3
		1	HYPERSOMNIA	神経系障害	過眠症	[redacted]20[redacted] -/ 11	[redacted]20[redacted] -/ 13	Y	RELATED	3
		9	LUNG INFECTION	感染症および寄生虫症	肺炎	[redacted]20[redacted] 16:40/ 66	[redacted]20[redacted] -/ 70	Y	NOT RELATED	1

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=12 mg - ESCALATION

Site ID- Subject ID- Patient ID	Country Gender Age	Analysis Acn Taken with Study Trt	Outcome of Adverse Event	Grade 1 Change/ Date Time	Grade 2 Change/ Date Time	Grade 3 Change/ Date Time	Grade 4 Change/ Date Time	Grade 5 Change/ Date Time	Grade 6 Change/ Date Time	Grade 7 Change/ Date Time	Grade 8 Change/ Date Time	Grade 9 Change/ Date Time
[redacted]	NLD F 7[redacted]	DOSE NOT CHANGED	RECOVERED/ RESOLVED	2/ [redacted]20[redacted]	-	-	-	-	-	-	-	-
		DRUG WITHDRAWN	FATAL	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	2/ [redacted]20[redacted]	-	-	-	-	-	-	-	-
[redacted]	GBR F 7[redacted]	DRUG INTERRUPTED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DRUG INTERRUPTED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DRUG INTERRUPTED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Site ID- Subject ID- Patient ID	Country Gender Age	Treatment Start Date/ End Date
Dose leve=12 mg - ESCALATION		
[redacted]	NLD F 7[redacted]	[redacted]20[redacted]/ 20[redacted]
		[redacted]20[redacted]/ 20[redacted]
		[redacted]20[redacted]/ 20[redacted]
[redacted]	GBR F 7[redacted]	[redacted]20[redacted]/ 20[redacted]
		[redacted]20[redacted]/ 20[redacted]
		[redacted]20[redacted]/ 20[redacted]

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=12 mg - ESCALATION

Site ID- Subject ID- Patient ID	Country Gender Age	Spons or ID	AE Term	Body System or Organ Class	Dictionary- Derived Term	AE Start Date/ Day	AE End Date/ Day	Treatment Emergent Analysis Flag	Analysis Causality	Grade
[redacted]	GBR F 7[redacted]	8	GRAM NEGATIVE BACILLI BACTEREMIA	感染症および寄生 虫症	菌血症	[redacted]20[redacted] 11:00/ 2	[redacted]20[redacted] -/ 8	Y	NOT RELATED	3

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=12 mg - ESCALATION

Site ID- Subject ID- Patient ID	Country Gender Age	Analysis Acn Taken with Study Trt	Outcome of Adverse Event	Grade 1 Change/ Date Time	Grade 2 Change/ Date Time	Grade 3 Change/ Date Time	Grade 4 Change/ Date Time	Grade 5 Change/ Date Time	Grade 6 Change/ Date Time	Grade 7 Change/ Date Time	Grade 8 Change/ Date Time	Grade 9 Change/ Date Time
[redacted]	GBR F 7[redacted]	DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=12 mg - ESCALATION		
Site ID- Subject ID- Patient ID	Country Gender Age	Treatment Start Date/ End Date
[redacted]	GBR F 7[redacted]	[redacted]20[redacted]/ [redacted]20[redacted]

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=24 mg - ESCALATION

Site ID- Subject ID- Patient ID	Country Gender Age	Sponsor ID	AE Term	Body System or Organ Class	Dictionary-Derived Term	AE Start Date/ Day	AE End Date/ Day	Treatment Emergent Analysis Flag	Analysis Causality	Grade
[redacted]	DNK M 8[redacted]	2	CYTOKINE RELEASE SYNDROME	免疫系障害	サイトカイン放出症候群	[redacted]20[redacted] 01:29/ 18	[redacted]20[redacted] 10:00/ 22	Y	RELATED	2
		3	CYTOKINE RELEASE SYNDROME	免疫系障害	サイトカイン放出症候群	[redacted]20[redacted] 23:14/ 60	[redacted]20[redacted] 14:17/ 65	Y	RELATED	2
		24	FEVER	一般・全身障害および投与部位の状態	発熱	[redacted]20[redacted] 01:29/ 18	[redacted]20[redacted] 05:45/ 18	Y	RELATED	1
		25	HYPOXEMIA	呼吸器、胸郭および縦隔障害	低酸素症	[redacted]20[redacted] 04:03/ 18	[redacted]20[redacted] 11:09/ 22	Y	RELATED	2
		29	HYPOTENSION	血管障害	低血圧	[redacted]20[redacted] 05:45/ 18	[redacted]20[redacted] 07:43/ 18	Y	RELATED	2
		33	FEVER	一般・全身障害および投与部位の状態	発熱	[redacted]20[redacted] 23:14/ 60	[redacted]20[redacted] 00:45/ 61	Y	RELATED	1

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=24 mg - ESCALATION

Site ID-Subject ID-Patient ID	Country Gender Age	Analysis Acn Taken with Study Trt	Outcome of Adverse Event	Grade 1 Change/ Date Time	Grade 2 Change/ Date Time	Grade 3 Change/ Date Time	Grade 4 Change/ Date Time	Grade 5 Change/ Date Time	Grade 6 Change/ Date Time	Grade 7 Change/ Date Time	Grade 8 Change/ Date Time	Grade 9 Change/ Date Time
[redacted]	DNK M 8[redacted]	DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Site ID- Subject ID- Patient ID	Country Gender Age	Treatment Start Date/ End Date
[redacted]	DNK M 8[redacted]	[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]

Dose leve=24 mg - ESCALATION

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=24 mg - ESCALATION

Site ID- Subject ID- Patient ID	Country Gender Age	Sponsor ID	AE Term	Body System or Organ Class	Dictionary-Derived Term	AE Start Date/ Day	AE End Date/ Day	Treatment Emergent Analysis Flag	Analysis Causality	Grade
[redacted]	DNK M 8[redacted]	34	HYPOXEMIA	呼吸器、胸郭および縦隔障害	低酸素症	[redacted]20[redacted] 23:14/ 60	[redacted]20[redacted] 14:17/ 65	Y	RELATED	2
		47	PAIN IN CHEST DUE TO FRACTURA COSTA 10-12 LEFT SIDE.	筋骨格系および結合組織障害	骨折痛	[redacted]20[redacted] -/ 146	[redacted]20[redacted] -/ 227	Y	NOT RELATED	3
		62	LUNG STASIS	呼吸器、胸郭および縦隔障害	肺うっ血	[redacted]20[redacted] 10:00/ 379	[redacted]20[redacted] -/ 383	Y	NOT RELATED	2
		69	PNEUMONIA	感染症および寄生虫症	肺炎	[redacted]20[redacted] 11:50/ 619	[redacted]20[redacted] -/ 626	Y	NOT RELATED	3
		74	CARDIAC FAILURE	心臓障害	心不全	[redacted]20[redacted] -/ 654		Y	NOT RELATED	3
[redacted]	ESP F 7[redacted]	1	CYTOKINE RELEASE SYNDROME	免疫系障害	サイトカイン放出症候群	[redacted]20[redacted] 16:54/ 17	[redacted]20[redacted] 14:00/ 23	Y	RELATED	1

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=24 mg - ESCALATION

Site ID- Subject ID- Patient ID	Country Gender Age	Analysis Acn Taken with Study Trt	Outcome of Adverse Event	Grade 1 Change/ Date Time	Grade 2 Change/ Date Time	Grade 3 Change/ Date Time	Grade 4 Change/ Date Time	Grade 5 Change/ Date Time	Grade 6 Change/ Date Time	Grade 7 Change/ Date Time	Grade 8 Change/ Date Time	Grade 9 Change/ Date Time
[redacted]	DNK M 8[redacted]	DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	1/ [redacted]20[redacted]	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DRUG INTERRUPTED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	NOT RECOVERED/ NOT RESOLVED	3/ [redacted]20[redacted] 11:35	2/ [redacted]20[redacted] 10:15	-	-	-	-	-	-	-
[redacted]	ESP F 7[redacted]	DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Site ID- Subject ID- Patient ID	Country Gender Age	Treatment Start Date/ End Date
Dose leve=24 mg - ESCALATION		
[redacted]	DNK M 8[redacted]	[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
[redacted]	ESP F 7[redacted]	[redacted]20[redacted]/ [redacted]20[redacted]

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=24 mg - ESCALATION

Site ID- Subject ID- Patient ID	Country Gender Age	Sponsor ID	AE Term	Body System or Organ Class	Dictionary-Derived Term	AE Start Date/ Day	AE End Date/ Day	Treatment Emergent Analysis Flag	Analysis Causality	Grade
[redacted]	ESP F 7[redacted]	1	FEVER	一般・全身障害および投与部位の状態	発熱	[redacted]20[redacted] 14:20/ 16	[redacted]20[redacted] 21:03/ 19	Y	RELATED	2
		3	FEVER	一般・全身障害および投与部位の状態	発熱	[redacted]20[redacted] 15:34/ 35	[redacted]20[redacted] 14:00/ 44	Y	NOT RELATED	1
		4	DISEASE PROGRESSION	良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	悪性新生物進行	[redacted]20[redacted] -/ 37	[redacted]20[redacted] -/ 50	Y	NOT RELATED	5
[redacted]	NLD M 7[redacted]	1	ＣＯＶＩＤ－１９ PNEUMONITIS	感染症および寄生虫症	ＣＯＶＩＤ－１９肺炎	[redacted]20[redacted] 09:17/ 8	[redacted]20[redacted] -/ 32	Y	NOT RELATED	3
[redacted]	GBR F 6[redacted]	1	NEUROLOGICAL SYMPTOMS	神経系障害	神経学的症状	[redacted]20[redacted] -/ 35	[redacted]20[redacted] -/ 36	Y	RELATED	3
		2	NEUROLOGICAL SYMPTOMS	神経系障害	神経学的症状	[redacted]20[redacted] -/ 49	[redacted]20[redacted] -/ 57	Y	RELATED	3

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=24 mg - ESCALATION

Site ID- Subject ID- Patient ID	Country Gender Age	Analysis Acn Taken with Study Trt	Outcome of Adverse Event	Grade 1 Change/ Date Time	Grade 2 Change/ Date Time	Grade 3 Change/ Date Time	Grade 4 Change/ Date Time	Grade 5 Change/ Date Time	Grade 6 Change/ Date Time	Grade 7 Change/ Date Time	Grade 8 Change/ Date Time	Grade 9 Change/ Date Time
[redacted]	ESP F 7[redacted]	DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DRUG WITHDRAWN	FATAL	-	-	-	-	-	-	-	-	-
[redacted]	NLD M 7[redacted]	DRUG INTERRUPTE D	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
[redacted]	GBR F 6[redacted]	DRUG INTERRUPTE D	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=24 mg - ESCALATION		
Site ID- Subject ID- Patient ID	Country Gender Age	Treatment Start Date/ End Date
[redacted]	ESP F 7[redacted]	[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
[redacted]	NLD M 7[redacted]	[redacted]20[redacted]/ [redacted]20[redacted]
[redacted]	GBR F 6[redacted]	[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=24 mg - ESCALATION

Site ID- Subject ID- Patient ID	Country Gender Age	Sponsor ID	AE Term	Body System or Organ Class	Dictionary-Derived Term	AE Start Date/ Day	AE End Date/ Day	Treatment Emergent Analysis Flag	Analysis Causality	Grade
[redacted]	GBR F 6[redacted]	4	NEUROLOGICAL SYMPTOMS	神経系障害	神経学的症状	[redacted]20[redacted] -/ 5	[redacted]20[redacted] -/ 7	Y	RELATED	2
		1	ACUTE KIDNEY INJURY	腎および尿路障害	急性腎障害	[redacted]20[redacted] -/ -15	[redacted]20[redacted] -/ -1		NOT RELATED	3
		11	DEPRESSED LEVEL OF CONCIOUSNESS	神経系障害	意識レベルの低下	[redacted]20[redacted] -/ 49	[redacted]20[redacted] -/ 57	Y	RELATED	3
		15	DISEASE PROGRESSION	良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	悪性新生物進行	[redacted]20[redacted] -/ 49	[redacted]20[redacted] -/ 62	Y	NOT RELATED	5
		16	DEPRESSED LEVEL OF CONSCIOUSNESS	神経系障害	意識レベルの低下	[redacted]20[redacted] -/ 5	[redacted]20[redacted] -/ 7	Y	RELATED	2
		18	CONFUSION	精神障害	錯乱状態	[redacted]20[redacted] -/ 5	[redacted]20[redacted] -/ 7	Y	RELATED	1

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=24 mg - ESCALATION

Site ID-Subject ID-Patient ID	Country Gender Age	Analysis Acn Taken with Study Trt	Outcome of Adverse Event	Grade 1 Change/ Date Time	Grade 2 Change/ Date Time	Grade 3 Change/ Date Time	Grade 4 Change/ Date Time	Grade 5 Change/ Date Time	Grade 6 Change/ Date Time	Grade 7 Change/ Date Time	Grade 8 Change/ Date Time	Grade 9 Change/ Date Time
[redacted]	GBR F 6[redacted]	DRUG INTERRUPTED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		NOT APPLICABLE	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DRUG WITHDRAWN	FATAL	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DRUG INTERRUPTED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Site ID- Subject ID- Patient ID	Country Gender Age	Treatment Start Date/ End Date
[redacted]	GBR F 6[redacted]	[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]

Dose leve=24 mg - ESCALATION

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=24 mg - ESCALATION

Site ID- Subject ID- Patient ID	Country Gender Age	Sponsor ID	AE Term	Body System or Organ Class	Dictionary-Derived Term	AE Start Date/ Day	AE End Date/ Day	Treatment Emergent Analysis Flag	Analysis Causality	Grade
[redacted]	GBR F 6[redacted]	5	RESPIRATORY TRACT INFECTION (INFLUENZA A)	感染症および寄生虫症	インフルエンザ	[redacted]20[redacted] -/ 6	[redacted]20[redacted] -/ 15	Y	NOT RELATED	2
		6	WORSENING OF SACRAL PAIN	筋骨格系および結合組織障害	仙骨痛	[redacted]20[redacted] -/ 15		Y	NOT RELATED	3
		9	CONFUSION	精神障害	錯乱状態	[redacted]20[redacted] -/ 35	[redacted]20[redacted] -/ 36	Y	RELATED	3
[redacted]	GBR M 6[redacted]	2	CYTOKINE RELEASE SYNDROME	免疫系障害	サイトカイン放出症候群	[redacted]20[redacted] 17:00/ 18	[redacted]20[redacted] 13:00/ 22	Y	RELATED	1
		1	RASH	皮膚および皮下組織障害	発疹	[redacted]20[redacted] 17:00/ 18	[redacted]20[redacted] -/ 22	Y	RELATED	2
[redacted]	GBR F 7[redacted]	1	CYTOKINE RELEASE SYNDROME	免疫系障害	サイトカイン放出症候群	[redacted]20[redacted] 09:00/ 16	[redacted]20[redacted] -/ 17	Y	RELATED	2

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=24 mg - ESCALATION

Site ID-Subject ID-Patient ID	Country Gender Age	Analysis Acn Taken with Study Trt	Outcome of Adverse Event	Grade 1 Change/ Date Time	Grade 2 Change/ Date Time	Grade 3 Change/ Date Time	Grade 4 Change/ Date Time	Grade 5 Change/ Date Time	Grade 6 Change/ Date Time	Grade 7 Change/ Date Time	Grade 8 Change/ Date Time	Grade 9 Change/ Date Time
[redacted]	GBR F 6[redacted]	DRUG INTERRUPTED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	NOT RECOVERED/ NOT RESOLVED	3/ [redacted]20[redacted]	-	-	-	-	-	-	-	-
		DRUG INTERRUPTED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
[redacted]	GBR M 6[redacted]	DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
[redacted]	GBR F 7[redacted]	DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=24 mg - ESCALATION		
Site ID- Subject ID- Patient ID	Country Gender Age	Treatment Start Date/ End Date
[redacted]	GBR F 6[redacted]	[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
[redacted]	GBR M 6[redacted]	[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
[redacted]	GBR F 7[redacted]	[redacted]20[redacted]/ [redacted]20[redacted]

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=24 mg - ESCALATION

Site ID- Subject ID- Patient ID	Country Gender Age	Sponsor ID	AE Term	Body System or Organ Class	Dictionary-Derived Term	AE Start Date/ Day	AE End Date/ Day	Treatment Emergent Analysis Flag	Analysis Causality	Grade
[redacted]	GBR F 7[redacted]	13	RE-OCCURRING CONSTIPATION	胃腸障害	便秘	[redacted]20[redacted] -/ 27	[redacted]20[redacted] -/ 38	Y	NOT RELATED	2
		2	CONSTIPATION	胃腸障害	便秘	[redacted]20[redacted] -/ 21	[redacted]20[redacted] -/ 26	Y	NOT RELATED	2
		6	FEVER	一般・全身障害および投与部位の状態	発熱	[redacted]20[redacted] 09:00/ 16	[redacted]20[redacted] -/ 17	Y	RELATED	2

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=24 mg - ESCALATION

Site ID- Subject ID- Patient ID	Country Gender Age	Analysis Acn Taken with Study Trt	Outcome of Adverse Event	Grade 1 Change/ Date Time	Grade 2 Change/ Date Time	Grade 3 Change/ Date Time	Grade 4 Change/ Date Time	Grade 5 Change/ Date Time	Grade 6 Change/ Date Time	Grade 7 Change/ Date Time	Grade 8 Change/ Date Time	Grade 9 Change/ Date Time
[redacted]	GBR F 7[redacted]	DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Site ID- Subject ID- Patient ID	Country Gender Age	Treatment Start Date/ End Date
[redacted]	GBR F 7[redacted]	[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]

Dose leve=24 mg - ESCALATION

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=48 mg - ESCALATION

Site ID- Subject ID- Patient ID	Country Gender Age	Sponsor ID	AE Term	Body System or Organ Class	Dictionary-Derived Term	AE Start Date/ Day	AE End Date/ Day	Treatment Emergent Analysis Flag	Analysis Causality	Grade
[redacted]	DNK M 6[redacted]	1	CYTOKINE RELEASE SYNDROME	免疫系障害	サイトカイン放出症候群	[redacted]20[redacted] 23:00/ 11	[redacted]20[redacted] 16:21/ 15	Y	RELATED	1
		3	CYTOKINE RELEASE SYNDROME	免疫系障害	サイトカイン放出症候群	[redacted]20[redacted] -/ 18	[redacted]20[redacted] -/ 21	Y	RELATED	2
		10	MUSCLE TENDERNESS	筋骨格系および結合組織障害	筋肉痛	[redacted]20[redacted] 21:33/ 18	[redacted]20[redacted] 10:24/ 23	Y	RELATED	1
		11	FATIQUE	一般・全身障害および投与部位の状態	疲労	[redacted]20[redacted] 21:33/ 18	[redacted]20[redacted] 10:24/ 23	Y	RELATED	1
		13	HEADCHE	神経系障害	頭痛	[redacted]20[redacted] -/ 11	[redacted]20[redacted] -/ 12	Y	RELATED	1
		5	FEVER	一般・全身障害および投与部位の状態	発熱	[redacted]20[redacted] 20:00/ 11	[redacted]20[redacted] 16:21/ 12	Y	RELATED	2

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=48 mg - ESCALATION

Site ID-Subject ID-Patient ID	Country Gender Age	Analysis Acn Taken with Study Trt	Outcome of Adverse Event	Grade 1 Change/ Date Time	Grade 2 Change/ Date Time	Grade 3 Change/ Date Time	Grade 4 Change/ Date Time	Grade 5 Change/ Date Time	Grade 6 Change/ Date Time	Grade 7 Change/ Date Time	Grade 8 Change/ Date Time	Grade 9 Change/ Date Time
[redacted]	DNK M 6[redacted]	DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DRUG INTERRUPTED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DRUG INTERRUPTED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DRUG INTERRUPTED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	2/ [redacted]20[redacted] 23:00	-	-	-	-	-	-	-	-

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Site ID- Subject ID- Patient ID	Country Gender Age	Treatment Start Date/ End Date
[redacted]	DNK M 6[redacted]	[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]

Dose leve=48 mg - ESCALATION

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=48 mg - ESCALATION

Site ID- Subject ID- Patient ID	Country Gender Age	Spons or ID	AE Term	Body System or Organ Class	Dictionary-Derived Term	AE Start Date/ Day	AE End Date/ Day	Treatment Emergent Analysis Flag	Analysis Causality	Grade
[redacted]	DNK M 6[redacted]	9	FEVER	一般・全身障害および投与部位の状態	発熱	[redacted]20[redacted] 21:33/ 18	[redacted]20[redacted] 10:24/ 21	Y	RELATED	1
[redacted]	DNK M 7[redacted]	2	CYTOKINE RELEASE SYNDROME	免疫系障害	サイトカイン放出症候群	[redacted]20[redacted] 18:00/ 11	[redacted]20[redacted] 08:41/ 14	Y	RELATED	1
		3	CYTOKINE RELEASE SYNDROME	免疫系障害	サイトカイン放出症候群	[redacted]20[redacted] 04:14/ 16	[redacted]20[redacted] 23:10/ 21	Y	RELATED	1
		2	FEVER (CRS)	一般・全身障害および投与部位の状態	発熱	[redacted]20[redacted] 18:00/ 11	[redacted]20[redacted] 19:45/ 13	Y	RELATED	1
		3	FEVER (CRS)	一般・全身障害および投与部位の状態	発熱	[redacted]20[redacted] 04:14/ 16	[redacted]20[redacted] 23:10/ 21	Y	RELATED	2
		6	STAPHYLOCOCUS EPIDERMIS IV SITE (LEFT ARM)	感染症および寄生虫症	ブドウ球菌感染	[redacted]20[redacted] -/ 21	[redacted]20[redacted] -/ 28	Y	NOT RELATED	2

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=48 mg - ESCALATION

Site ID- Subject ID- Patient ID	Country Gender Age	Analysis Acn Taken with Study Trt	Outcome of Adverse Event	Grade 1 Change/ Date Time	Grade 2 Change/ Date Time	Grade 3 Change/ Date Time	Grade 4 Change/ Date Time	Grade 5 Change/ Date Time	Grade 6 Change/ Date Time	Grade 7 Change/ Date Time	Grade 8 Change/ Date Time	Grade 9 Change/ Date Time
[redacted]	DNK M 6[redacted]	DRUG INTERRUPTE D	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
[redacted]	DNK M 7[redacted]	DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	2/[redacted]20[redacted] 10:05	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Site ID- Subject ID- Patient ID	Country Gender Age	Treatment Start Date/ End Date
[redacted]	DNK M 6[redacted]	[redacted]20[redacted]/ [redacted]20[redacted]
[redacted]	DNK M 7[redacted]	[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]

Dose leve=48 mg - ESCALATION

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=48 mg - ESCALATION

Site ID- Subject ID- Patient ID	Country Gender Age	Sponsor ID	AE Term	Body System or Organ Class	Dictionary-Derived Term	AE Start Date/ Day	AE End Date/ Day	Treatment Emergent Analysis Flag	Analysis Causality	Grade
[redacted]	DNK M 8[redacted]	3	ATRIAL FLUTTER	心臓障害	心房粗動	[redacted]20[redacted] -/ -8	[redacted]20[redacted] -/ -6		NOT RELATED	2
		5	IMPAIRED GENERAL CONDITION	一般・全身障害および投与部位の状態	全身健康状態悪化	[redacted]20[redacted] -/ 18	[redacted]20[redacted] -/ 23	Y	NOT RELATED	5
[redacted]	ESP M 6[redacted]	1	CYTOKINE RELEASE SYNDROME	免疫系障害	サイトカイン放出症候群	[redacted]20[redacted] -/ 18	[redacted]20[redacted] -/ 21	Y	RELATED	1
		1	FEVER	一般・全身障害および投与部位の状態	発熱	[redacted]20[redacted] -/ 18	[redacted]20[redacted] -/ 20	Y	RELATED	1
[redacted]	ESP M 2[redacted]	1	CYTOKINE RELEASE SYNDROME	免疫系障害	サイトカイン放出症候群	[redacted]20[redacted] -/ 6	[redacted]20[redacted] -/ 8	Y	RELATED	2
		10	DISEASE PROGRESSION	良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	悪性新生物進行	[redacted]20[redacted] -/ 31	[redacted]20[redacted] -/ 31	Y	NOT RELATED	5

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=48 mg - ESCALATION

Site ID- Subject ID- Patient ID	Country Gender Age	Analysis Acn Taken with Study Trt	Outcome of Adverse Event	Grade 1 Change/ Date Time	Grade 2 Change/ Date Time	Grade 3 Change/ Date Time	Grade 4 Change/ Date Time	Grade 5 Change/ Date Time	Grade 6 Change/ Date Time	Grade 7 Change/ Date Time	Grade 8 Change/ Date Time	Grade 9 Change/ Date Time
[redacted]	DNK M 8[redacted]	NOT APPLICABLE	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		NOT APPLICABLE	FATAL	-	-	-	-	-	-	-	-	-
[redacted]	ESP M 6[redacted]	DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
[redacted]	ESP M 2[redacted]	DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		NOT APPLICABLE	FATAL	-	-	-	-	-	-	-	-	-

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Site ID- Subject ID- Patient ID	Country Gender Age	Treatment Start Date/ End Date
Dose leve=48 mg - ESCALATION		
[redacted]	DNK M 8[redacted]	[redacted]20[redacted]/ 20[redacted]
		[redacted]20[redacted]/ 20[redacted]
[redacted]	ESP M 6[redacted]	[redacted]20[redacted]/ 20[redacted]
		[redacted]20[redacted]/ 20[redacted]
[redacted]	ESP M 2[redacted]	[redacted]20[redacted]/ 20[redacted]
		[redacted]20[redacted]/ 20[redacted]

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=48 mg - ESCALATION

Site ID- Subject ID- Patient ID	Country Gender Age	Sponsor ID	AE Term	Body System or Organ Class	Dictionary-Derived Term	AE Start Date/ Day	AE End Date/ Day	Treatment Emergent Analysis Flag	Analysis Causality	Grade
[redacted]	ESP M 2[redacted]	3	FEVER	一般・全身障害および投与部位の状態	発熱	[redacted]20[redacted] -/ 6	[redacted]20[redacted] -/ 8	Y	RELATED	2
		6	RETROPERITONEAL HEMORRHAGE	胃腸障害	後腹膜出血	[redacted]20[redacted] -/ 20	[redacted]20[redacted] -/ 22	Y	NOT RELATED	4
		8	PLEURAL EFFUSION	呼吸器、胸郭および縦隔障害	胸水	[redacted]20[redacted] -/ 6	[redacted]20[redacted] -/ 16	Y	NOT RELATED	2
[redacted]	NLD M 6[redacted]	1	CYTOKINE RELEASE SYNDROME	免疫系障害	サイトカイン放出症候群	[redacted]20[redacted] -/ 16	[redacted]20[redacted] 10:28/ 16	Y	RELATED	2
		17	FATIQUE	一般・全身障害および投与部位の状態	疲労	[redacted]20[redacted] 12:14/ 79	[redacted]20[redacted] 08:04/ 82	Y	NOT RELATED	3
		3	FEVER	一般・全身障害および投与部位の状態	発熱	[redacted]20[redacted] -/ 16	[redacted]20[redacted] 05:35/ 16	Y	RELATED	2

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=48 mg - ESCALATION

Site ID- Subject ID- Patient ID	Country Gender Age	Analysis Acn Taken with Study Trt	Outcome of Adverse Event	Grade 1 Change/ Date Time	Grade 2 Change/ Date Time	Grade 3 Change/ Date Time	Grade 4 Change/ Date Time	Grade 5 Change/ Date Time	Grade 6 Change/ Date Time	Grade 7 Change/ Date Time	Grade 8 Change/ Date Time	Grade 9 Change/ Date Time
[redacted]	ESP M 2[redacted]	DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DRUG INTERRUPTED	RECOVERED/ RESOLVED	1/ [redacted]20[redacted]	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
[redacted]	NLD M 6[redacted]	DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Site ID- Subject ID- Patient ID	Country Gender Age	Treatment Start Date/ End Date
Dose leve=48 mg - ESCALATION		
[redacted]	ESP M 2[redacted]	[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
[redacted]	NLD M 6[redacted]	[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=48 mg - ESCALATION

Site ID-Subject ID-Patient ID	Country Gender Age	Sponsor ID	AE Term	Body System or Organ Class	Dictionary-Derived Term	AE Start Date/Day	AE End Date/Day	Treatment Emergent Analysis Flag	Analysis Causality	Grade
[redacted]	NLD M 6[redacted]	8	NAUSEA	胃腸障害	悪心	[redacted]20[redacted] -/ 16	[redacted]20[redacted] -/ 16	Y	RELATED	1
		9	CHILLS	一般・全身障害および投与部位の状態	悪寒	[redacted]20[redacted] -/ 16	[redacted]20[redacted] -/ 16	Y	RELATED	1
[redacted]	NLD M 7[redacted]	1	CYTOKINE RELEASE SYNDROME	免疫系障害	サイトカイン放出症候群	[redacted]20[redacted] 07:07/ 11	[redacted]20[redacted] -/ 12	Y	RELATED	2
		2	CYTOKINE RELEASE SYNDROME	免疫系障害	サイトカイン放出症候群	[redacted]20[redacted] -/ 24	[redacted]20[redacted] -/ 25	Y	RELATED	2
		1	FEVER	一般・全身障害および投与部位の状態	発熱	[redacted]20[redacted] 07:07/ 11	[redacted]20[redacted] 11:44/ 11	Y	RELATED	1
		10	HYPOTENSION	血管障害	低血圧	[redacted]20[redacted] -/ 24	[redacted]20[redacted] -/ 24	Y	RELATED	2

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=48 mg - ESCALATION

Site ID-Subject ID-Patient ID	Country Gender Age	Analysis Acn Taken with Study Trt	Outcome of Adverse Event	Grade 1 Change/ Date Time	Grade 2 Change/ Date Time	Grade 3 Change/ Date Time	Grade 4 Change/ Date Time	Grade 5 Change/ Date Time	Grade 6 Change/ Date Time	Grade 7 Change/ Date Time	Grade 8 Change/ Date Time	Grade 9 Change/ Date Time
[redacted]	NLD M 6[redacted]	DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
[redacted]	NLD M 7[redacted]	DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Site ID- Subject ID- Patient ID	Country Gender Age	Treatment Start Date/ End Date
Dose leve=48 mg - ESCALATION		
[redacted]	NLD M 6[redacted]	[redacted]20[redacted]/ 20[redacted]
		[redacted]20[redacted]/ 20[redacted]
[redacted]	NLD M 7[redacted]	[redacted]20[redacted]/ 20[redacted]
		[redacted]20[redacted]/ 20[redacted]
		[redacted]20[redacted]/ 20[redacted]
		[redacted]20[redacted]/ 20[redacted]

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=48 mg - ESCALATION

Site ID- Subject ID- Patient ID	Country Gender Age	Sponsor ID	AE Term	Body System or Organ Class	Dictionary-Derived Term	AE Start Date/ Day	AE End Date/ Day	Treatment Emergent Analysis Flag	Analysis Causality	Grade
[redacted]	NLD M 7[redacted]	11	TACHYCARDIA	心臓障害	頻脈	[redacted]20[redacted] -/ 24	[redacted]20[redacted] -/ 24	Y	RELATED	2
		2	HYPOXIA	呼吸器、胸郭および縦隔障害	低酸素症	[redacted]20[redacted] 07:07/ 11	[redacted]20[redacted] -/ 33	Y	RELATED	2
		28	COPD EXACERBATION	呼吸器、胸郭および縦隔障害	慢性閉塞性肺疾患	[redacted]20[redacted] -/ 78		Y	NOT RELATED	3
		3	HYPOTENSION	血管障害	低血圧	[redacted]20[redacted] 07:07/ 11	[redacted]20[redacted] 16:31/ 11	Y	RELATED	2
		4	PNEUMONIA	感染症および寄生虫症	肺炎	[redacted]20[redacted] -/ 11	[redacted]20[redacted] -/ 33	Y	NOT RELATED	3
		9	FEVER	一般・全身障害および投与部位の状態	発熱	[redacted]20[redacted] -/ 24	[redacted]20[redacted] -/ 24	Y	RELATED	1

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=48 mg - ESCALATION

Site ID-Subject ID-Patient ID	Country Gender Age	Analysis Acn Taken with Study Trt	Outcome of Adverse Event	Grade 1 Change/ Date Time	Grade 2 Change/ Date Time	Grade 3 Change/ Date Time	Grade 4 Change/ Date Time	Grade 5 Change/ Date Time	Grade 6 Change/ Date Time	Grade 7 Change/ Date Time	Grade 8 Change/ Date Time	Grade 9 Change/ Date Time
[redacted]	NLD M 7[redacted]	DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DRUG INTERRUPTED	NOT RECOVERED/ NOT RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DRUG INTERRUPTED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Site ID- Subject ID- Patient ID	Country Gender Age	Treatment Start Date/ End Date
[redacted]	NLD M 7[redacted]	[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]

Dose leve=48 mg - ESCALATION

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=48 mg - ESCALATION

Site ID- Subject ID- Patient ID	Country Gender Age	Sponsor ID	AE Term	Body System or Organ Class	Dictionary-Derived Term	AE Start Date/ Day	AE End Date/ Day	Treatment Emergent Analysis Flag	Analysis Causality	Grade
[redacted]	NLD M 6[redacted]	3	CYTOKINE RELEASE SYNDROME	免疫系障害	サイトカイン放出症候群	[redacted]20[redacted] 03:33/ 15	[redacted]20[redacted] 23:37/ 17	Y	RELATED	1
		10	ATRIAL FIBRILLATION	心臓障害	心房細動	[redacted]20[redacted] 20:27/ 18	[redacted]20[redacted] 16:03/ 19	Y	NOT RELATED	2
		5	FEVER	一般・全身障害および投与部位の状態	発熱	[redacted]20[redacted] 03:33/ 15	[redacted]20[redacted] 23:37/ 17	Y	RELATED	2
		6	CHILLS	一般・全身障害および投与部位の状態	悪寒	[redacted]20[redacted] 03:33/ 15	[redacted]20[redacted] -/ 17	Y	RELATED	1
[redacted]	NLD M 4[redacted]	15	DIZZINESS (POSSIBLY RELATED TO OPIOD-USE)	神経系障害	浮動性めまい	[redacted]20[redacted] -/ 87	[redacted]20[redacted] -/ 108	Y	NOT RELATED	3
		4	STAPHYLOCOCCUS AUREUS BACTEREMIA	感染症および寄生虫症	ブドウ球菌性菌血症	[redacted]20[redacted] -/ 5	[redacted]20[redacted] -/ 55	Y	NOT RELATED	3

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=48 mg - ESCALATION

Site ID- Subject ID- Patient ID	Country Gender Age	Analysis Acn Taken with Study Trt	Outcome of Adverse Event	Grade 1 Change/ Date Time	Grade 2 Change/ Date Time	Grade 3 Change/ Date Time	Grade 4 Change/ Date Time	Grade 5 Change/ Date Time	Grade 6 Change/ Date Time	Grade 7 Change/ Date Time	Grade 8 Change/ Date Time	Grade 9 Change/ Date Time
[redacted]	NLD M 6[redacted]	DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	2/ [redacted]20[redacted] 05:13	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
[redacted]	NLD M 4[redacted]	DOSE NOT CHANGED	RECOVERED/ RESOLVED	3/ [redacted]20[redacted]	-	-	-	-	-	-	-	-
		DRUG INTERRUPTED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=48 mg - ESCALATION		
Site ID- Subject ID- Patient ID	Country Gender Age	Treatment Start Date/ End Date
[redacted]	NLD M 6[redacted]	[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
[redacted]	NLD M 4[redacted]	[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=48 mg - ESCALATION

Site ID- Subject ID- Patient ID	Country Gender Age	Sponsor ID	AE Term	Body System or Organ Class	Dictionary-Derived Term	AE Start Date/ Day	AE End Date/ Day	Treatment Emergent Analysis Flag	Analysis Causality	Grade
[redacted]	GBR M 7[redacted]	1	LUNG INFECTION (ＣＯＶＩＤ－１９)	感染症および寄生虫症	ＣＯＶＩＤ－１９肺炎	[redacted]20[redacted] -/ 18	[redacted]20[redacted] -/ 51	Y	NOT RELATED	5

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=48 mg - ESCALATION

Site ID- Subject ID- Patient ID	Country Gender Age	Analysis Acn Taken with Study Trt	Outcome of Adverse Event	Grade 1 Change/ Date Time	Grade 2 Change/ Date Time	Grade 3 Change/ Date Time	Grade 4 Change/ Date Time	Grade 5 Change/ Date Time	Grade 6 Change/ Date Time	Grade 7 Change/ Date Time	Grade 8 Change/ Date Time	Grade 9 Change/ Date Time
[redacted]	GBR M 7[redacted]	DRUG WITHDRAWN	FATAL	2/[redacted]20[redacted]	3/[redacted]20[redacted]	2/[redacted]20[redacted]	3/[redacted]20[redacted]	5/[redacted]20[redacted]	-	-	-	-

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=48 mg - ESCALATION		
Site ID- Subject ID- Patient ID	Country Gender Age	Treatment Start Date/ End Date
[redacted]	GBR M 7[redacted]	[redacted]20[redacted]/ [redacted]20[redacted]

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=60 mg - ESCALATION

Site ID-Subject ID-Patient ID	Country Gender Age	Sponsor ID	AE Term	Body System or Organ Class	Dictionary-Derived Term	AE Start Date/Day	AE End Date/Day	Treatment Emergent Analysis Flag	Analysis Causality	Grade
[redacted]	DNK M 6[redacted]	1	CYTOKINE RELEASE SYNDROME	免疫系障害	サイトカイン放出症候群	[redacted]20[redacted] 06:35/ 17	[redacted]20[redacted] 12:11/ 20	Y	RELATED	1
		11	SINUSTACHYCARDIA	心臓障害	頻脈	[redacted]20[redacted] 12:47/ 16	[redacted]20[redacted] 21:56/ 16	Y	RELATED	1
		12	FEVER	一般・全身障害および投与部位の状態	発熱	[redacted]20[redacted] 06:35/ 17	[redacted]20[redacted] 12:11/ 19	Y	RELATED	1
		29	ABDOMINAL PAIN	胃腸障害	腹痛	[redacted]20[redacted] 22:39/ 145	[redacted]20[redacted] 01:26/ 146	Y	NOT RELATED	2
		42	PNEUMONIA	感染症および寄生虫症	肺炎	[redacted]20[redacted] 11:08/ 623	[redacted]20[redacted] -/ 629	Y	NOT RELATED	3
[redacted]	ESP M 6[redacted]	1	CYTOKINE RELEASE SYNDROME	免疫系障害	サイトカイン放出症候群	[redacted]20[redacted] -/ 17	[redacted]20[redacted] 19:37/ 24	Y	RELATED	2

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=60 mg - ESCALATION

Site ID- Subject ID- Patient ID	Country Gender Age	Analysis Acn Taken with Study Trt	Outcome of Adverse Event	Grade 1 Change/ Date Time	Grade 2 Change/ Date Time	Grade 3 Change/ Date Time	Grade 4 Change/ Date Time	Grade 5 Change/ Date Time	Grade 6 Change/ Date Time	Grade 7 Change/ Date Time	Grade 8 Change/ Date Time	Grade 9 Change/ Date Time
[redacted]	DNK M 6[redacted]	DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DRUG INTERRUPTE D	RECOVERED/ RESOLVED	2/ [redacted]20[redacted] 10:13	-	-	-	-	-	-	-	-
[redacted]	ESP M 6[redacted]	DRUG INTERRUPTE D	RECOVERED/ RESOLVED	2/ [redacted]20[redacted] 16:14	-	-	-	-	-	-	-	-

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Site ID- Subject ID- Patient ID	Country Gender Age	Treatment Start Date/ End Date
[redacted]	DNK M 6[redacted]	[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
[redacted]	ESP M 6[redacted]	[redacted]20[redacted]/ [redacted]20[redacted]

Dose leve=60 mg - ESCALATION

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=60 mg - ESCALATION

Site ID- Subject ID- Patient ID	Country Gender Age	Sponsor ID	AE Term	Body System or Organ Class	Dictionary-Derived Term	AE Start Date/ Day	AE End Date/ Day	Treatment Emergent Analysis Flag	Analysis Causality	Grade
[redacted]	ESP M 6[redacted]	1	FEVER	一般・全身障害および投与部位の状態	発熱	[redacted]20[redacted] -/ 17	[redacted]20[redacted] -/ 24	Y	RELATED	1
		2	HEADACHE	神経系障害	頭痛	[redacted]20[redacted] -/ 19	[redacted]20[redacted] -/ 27	Y	RELATED	3
		3	ARTERIAL HYPOTENSION	血管障害	低血圧	[redacted]20[redacted] 16:14/ 19	[redacted]20[redacted] -/ 24	Y	RELATED	2

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=60 mg - ESCALATION

Site ID- Subject ID- Patient ID	Country Gender Age	Analysis Acn Taken with Study Trt	Outcome of Adverse Event	Grade 1 Change/ Date Time	Grade 2 Change/ Date Time	Grade 3 Change/ Date Time	Grade 4 Change/ Date Time	Grade 5 Change/ Date Time	Grade 6 Change/ Date Time	Grade 7 Change/ Date Time	Grade 8 Change/ Date Time	Grade 9 Change/ Date Time
[redacted]	ESP M 6[redacted]	DOSE NOT CHANGED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DRUG INTERRUPTED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-
		DRUG INTERRUPTED	RECOVERED/ RESOLVED	-	-	-	-	-	-	-	-	-

Table 67 Serious Adverse Events

Protocol: GCT3013-01
Safety Set.

Dose leve=60 mg - ESCALATION		
Site ID- Subject ID- Patient ID	Country Gender Age	Treatment Start Date/ End Date
[redacted]	ESP M 6[redacted]	[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]
		[redacted]20[redacted]/ [redacted]20[redacted]

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (6[redacted]/F/W/D)	/ [redacted]20[redacted] (13)	[redacted]20[redacted]:11:50	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (8[redacted]/M/W/D)	[redacted]20[redacted] (7)/ [redacted]20[redacted] (15)	[redacted]20[redacted]:12:40 (7)/ 9	臨床検査/ 血中クレアチニン増加/ CREATININE INCREASED#	NOT RELATED/ SAE [H]/ N	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (8[redacted]/M/A/D)	[redacted]20[redacted] (12)/ [redacted]20[redacted]:15:57 (14)	[redacted]20[redacted]:13:30 (5)/ 3	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (3[redacted]/M/W/D)	[redacted]20[redacted] (11)/ [redacted]20[redacted]:16:00 (13)	[redacted]20[redacted]:11:50 (4)/ 3	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L 3B.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (3[redacted]/M/W/D)	[redacted]20[redacted] (12)/ [redacted]20[redacted] (23)	[redacted]20[redacted]:11:50 (5)/ 12	感染症および寄生虫症/ 肺炎/ PNEUMONIA#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (7[redacted]/M/W/D)	[redacted]20[redacted] (16)/ [redacted]20[redacted]:23:32 (18)	[redacted]20[redacted]:12:10 (2)/ 3	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (5[redacted]/M/W/D)	[redacted]20[redacted] (78)	[redacted]20[redacted]:11:50 (14)	神経系障害/ ステロイド反応性脳橋血管周囲強化を伴う慢性リンパ球性炎症/ NERVOUS SYSTEM DISORDER-OTHER-CLIPPERS SYNDROME - WORSENING	RELATED/ SAE [H]/ N	Grade 3/ DRUG WITHDRAWN	Y/ NOT RECOVERED/NOT RESOLVED
	[redacted]20[redacted] (17)/ [redacted]20[redacted]:23:00 (18)	[redacted]20[redacted]:10:30 (2)/ 2	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L 3B.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (5[redacted]/M/W/D)	/ [redacted]20[redacted]:14:55 (10)	[redacted]20[redacted]:12:55	血液およびリンパ系障害/ 発熱性好中球減少症/ FEBRILE NEUTROPENIA#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted]20[redacted] (30)/ [redacted]20[redacted] (33)	[redacted]20[redacted]:12:35 (23)/ 4	胃腸障害/ 腹痛/ ABDOMINAL PAIN#	NOT RELATED/ SAE [H]/ N	Grade 3 (2)/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted]20[redacted] (21)/ [redacted]20[redacted] (29)	[redacted]20[redacted]:11:16 (6)/ 9	感染症および寄生虫症/ 敗血症/ SEPSIS#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
/ [redacted]20[redacted]:00:15 (13)	[redacted]20[redacted]:12:35	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	N/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L 3B.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (8[redacted]/M/O/D)	[redacted]20[redacted] (168)/ [redacted]20[redacted] (174)	[redacted]20[redacted]:12:30 (14)/ 7	感染症および寄生虫症/ 尿路性敗血症/ UROSEPSIS	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (255)	[redacted]20[redacted]:12:03 (17)	感染症および寄生虫症/ ＣＯＶＩＤ－１９肺炎/ COVID PNEUMONITIS	NOT RELATED/ SAE [L, H]/ N	Grade 3/ DRUG WITHDRAWN	Y/ NOT RECOVERED/NOT RESOLVED
	[redacted]20[redacted] (16)/ [redacted]20[redacted] (19)	[redacted]20[redacted]:11:28 (2)/ 4	感染症および寄生虫症/ ライノウイルス感染/ RHINOVIRUS INFECTION#	NOT RELATED/ SAE [H]/ N	Grade 1/ DOSE NOT CHANGED	N/ RECOVERED/RESOLVED
	[redacted]20[redacted] (16)/ [redacted]20[redacted]:19:21 (16)	[redacted]20[redacted]:11:28 (2)/ 1	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	N/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L 3B.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (6[redacted]/F/W/F)	/ [redacted]20[redacted]:10:30 (21)	[redacted]20[redacted]:12:35	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (6[redacted]/M/W/D)	[redacted]20[redacted] (20)/ [redacted]20[redacted] (24)	[redacted]20[redacted]:11:30 (6)/ 5	呼吸器、胸郭および縦隔障害/ 胸水/ PLEURAL EFFUSIONS#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (36)/ [redacted]20[redacted] (39)	[redacted]20[redacted]:14:26 (7)/ 4	呼吸器、胸郭および縦隔障害/ 低酸素症/ HYPOXIA#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (7[redacted]/M/W/F)	[redacted]20[redacted] (21)/ [redacted]20[redacted] (44)	[redacted]20[redacted]:12:00 (7)/ 24	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2 (1)/ DOSE DELAYED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L 3B.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (7[redacted]/M/W/F)	[redacted]20[redacted] (22)/ [redacted]20[redacted] (58)	[redacted]20[redacted]:13:25 (-6)/ 37	血管障害/ 低血圧/ INTERMITTENT HYPOTENSION#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
[redacted]20[redacted] (36)/ [redacted]20[redacted] (68)	[redacted]20[redacted]:12:43 (1)/ 33	心臓障害/ 頻脈/ INTERMITTENT TACHYCARDIA#	NOT RELATED/ SAE [H]/ N	Grade 2/ DOSE NOT CHANGED	N/ RECOVERED/RESOLVED
[redacted]20[redacted] (53)/ [redacted]20[redacted] (58)	[redacted]20[redacted]:17:45 (11)/ 6	感染症および寄生虫症/ ブドウ球菌性菌血症/ STAPH EPI BACTEREMIA#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
[redacted]20[redacted] (97)/ [redacted]20[redacted] (102)	[redacted]20[redacted]:11:57 (6)/ 6	感染症および寄生虫症/ 蜂巣炎/ CELLULITIS (L) LEG	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE DELAYED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L 3B.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (7[redacted]/M/W/F)	[redacted]20[redacted] (162)/ [redacted]20[redacted] (182)	[redacted]20[redacted]:13:45 (15)/ 21	感染症および寄生虫症/ 蜂巣炎/ CELLULITIS (L) LOWER LEG	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (185)/ [redacted]20[redacted] (224)	[redacted]20[redacted]:13:45 (38)/ 40	感染症および寄生虫症/ 蜂巣炎/ BILATERAL CELLULITIS LEG	NOT RELATED/ SAE [H]/ N	Grade 3/ NOT APPLICABLE	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (48)/ [redacted]20[redacted] (59)	[redacted]20[redacted]:17:45 (6)/ 12	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H, D]/ Y	Grade 2/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
[redacted] (6[redacted]/M/W/D)	[redacted]20[redacted] (7)/ [redacted]20[redacted] (25)	[redacted]20[redacted]:13:55 (7)/ 19	呼吸器、胸郭および縦隔障害/ 肺塞栓症/ PULMONARY EMBOLISM#	NOT RELATED/ SAE [F, H]/ N	Grade 5 (3)/ DOSE NOT CHANGED	Y/ FATAL

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L 3B.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (5[redacted]/F/W/D)	[redacted]20[redacted] (152)/ [redacted]20[redacted] (155)	[redacted]20[redacted]:10:31 (4)/ 4	感染症および寄生虫症/ 上気道感染/ UPPER RESPIRATORY TRACT INFECTION	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (257)/ [redacted]20[redacted] (263)	[redacted]20[redacted]:10:37 (11)/ 7	肝胆道系障害/ 胆管炎/ CHOLANGITIS	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
[redacted] (3[redacted]/F/W/D)	[redacted]20[redacted] (85)	[redacted]20[redacted]:10:46 (6)	精神障害/ 譫妄/ DELIRIUM (INCLUDES CONFUSION, AMNESIA, REDUCED LOC)	NOT RELATED/ SAE [H]/ N	Grade 3/ NOT APPLICABLE	N/ NOT RECOVERED/NOT RESOLVED
[redacted] (7[redacted]/M/W/D)	[redacted]20[redacted] (15)/ [redacted]20[redacted]:08:13 (28)	[redacted]20[redacted]:10:20 (8)/ 14	臨床検査/ Ｃ－反応性蛋白増加/ CRP INCREASED#	RELATED/ SAE [H]/ N	Grade 3/ DOSE DELAYED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L 3B.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (7[redacted]/M/W/D)	[redacted]20[redacted] (23)/ [redacted]20[redacted] (23)	[redacted]20[redacted]:09:50 (2)/ 1	神経系障害/ 免疫エフェクター細胞関連神経毒性症候群/ IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROM#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (57)	[redacted]20[redacted]:12:30 (1)	呼吸器、胸郭および縦隔障害/ 胸水/ PLEURAL EFFUSION	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	Y/ NOT RECOVERED/NOT RESOLVED
[redacted] (5[redacted]/M/W/D)	[redacted]20[redacted] (14)/ [redacted]20[redacted] (31)	[redacted]20[redacted]:14:30 (7)/ 18	胃腸障害/ 悪心/ NAUSEA#	RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (66)/ [redacted]20[redacted] (74)	[redacted]20[redacted]:14:45 (3)/ 9	感染症および寄生虫症/ 医療機器関連感染/ PORT INFECTION	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE DELAYED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L 3B.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (5[redacted]/M/W/D)	[redacted]20[redacted] (75)/ [redacted]20[redacted] (81)	[redacted]20[redacted]:14:45 (12)/ 7	血液およびリンパ系障害/ 発熱性好中球減少症/ FEBRILE NEUTROPENIA	RELATED/ SAE [H]/ N	Grade 3/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (138)/ [redacted]20[redacted] (152)	[redacted]20[redacted]:13:50 (12)/ 15	感染症および寄生虫症/ 敗血症/ SEPSIS	NOT RELATED/ SAE [H]/ N	Grade 3/ NOT APPLICABLE	Y/ RECOVERED/RESOLVED
[redacted] (5[redacted]/M/O/H)	[redacted]20[redacted] (14)	[redacted]20[redacted]:11:35 (7)	腎および尿路障害/ 急性腎障害/ RENAL AND URINARY DISORDERS - OTHER - ACUTE KIDNEY FAILURE#	NOT RELATED/ SAE [H, D]/ N	Grade 2/ DOSE DELAYED	Y/ NOT RECOVERED/NOT RESOLVED
[redacted] (7[redacted]/F/W/D)	/ [redacted]20[redacted]:08:35 (63)	[redacted]20[redacted]:11:07	一般・全身障害および投与部位の状態/ 発熱/ FEVER	NOT RELATED/ SAE [H]/ N	Grade 1/ DOSE DELAYED	N/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L 3B.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (7[redacted]/F/W/D)	[redacted]20[redacted] (106)	[redacted]20[redacted]:12:00 (36)	一般・全身障害および投与部位の状態/ 疲労/ WORSENING OF FATIGUE	NOT RELATED/ SAE [H]/ N	Grade 3 (2)/ DRUG WITHDRAWN	Y/ NOT RECOVERED/NOT RESOLVED
[redacted]20[redacted] (101)/ [redacted]20[redacted] (106)	[redacted]20[redacted]:13:30 (10)/ 6	心臓障害/ 心不全/ HEARTFAILURE	NOT RELATED/ SAE [L, H]/ N	Grade 3/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
/ [redacted]20[redacted]:11:41 (10)	[redacted]20[redacted]:11:25	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
/ [redacted]20[redacted]:09:34 (59)	[redacted]20[redacted]:11:07	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L 3B.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (7[redacted]/F/W/D)	[redacted]20[redacted] (71)/ [redacted]20[redacted]:06:23 (72)	[redacted]20[redacted]:12:00 (1)/ 2	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME	RELATED/ SAE [H]/ Y	Grade 2 (1)/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (95)/ [redacted]20[redacted]:02:00 (98)	[redacted]20[redacted]:13:30 (4)/ 4	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME	RELATED/ SAE [H]/ Y	Grade 2 (1)/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (99)/ [redacted]20[redacted] (101)	[redacted]20[redacted]:13:30 (8)/ 3	呼吸器、胸郭および縦隔障害/ 胸水/ PLEURAEFFUSION	NOT RELATED/ SAE [H]/ N	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (116)/ [redacted]20[redacted]:19:00 (117)	[redacted]20[redacted]:11:20 (11)/ 2	免疫系障害/ サイトカイン放出症候群/ CYTOKIN RELEASE SYNDROME	RELATED/ SAE [H]/ Y	Grade 1/ DRUG WITHDRAWN	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L 3B.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (7[redacted]/F/W/D)	[redacted]20[redacted] (117)/ [redacted]20[redacted]:14:00 (124)	[redacted]20[redacted]:11:20 (12)/ 8	感染症および寄生虫症/ 尿路感染/ URINE TRACT INFECTION	NOT RELATED/ SAE [H]/ N	Grade 2/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
[redacted] (7[redacted]/F/W/D)	/ [redacted]20[redacted]:12:30 (16)	[redacted]20[redacted]:10:30	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	/ [redacted]20[redacted]:06:30 (22)	[redacted]20[redacted]:10:30	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (5[redacted]/M/W/D)	/ [redacted]20[redacted] (11)	[redacted]20[redacted]:13:29	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2 (1)/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L 3B.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (5[redacted]/M/W/D)	/ [redacted]20[redacted] (17)	[redacted]20[redacted]:12:40	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2 (1)/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (6[redacted]/F/W/H)	[redacted]20[redacted] (17)/ [redacted]20[redacted] (29)	[redacted]20[redacted]:12:45 (3)/ 13	呼吸器、胸郭および縦隔障害/ 胸水/ PLEURAL EFFUSION#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (55)/ [redacted]20[redacted]:04:02 (56)	[redacted]20[redacted]:14:05 (6)/ 2	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
[redacted] (5[redacted]/F/W/F)	[redacted]20[redacted] (49)		感染症および寄生虫症/ 進行性多巣性白質脳症/ PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY*	NOT RELATED/ SAE [L, H]/ N	Grade 4/ NOT APPLICABLE	N/ NOT RECOVERED/NOT RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L 3B.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (5[redacted]/F/W/F)	[redacted]20[redacted] (20)/ [redacted]20[redacted] (22)	[redacted]20[redacted]:10:55 (14)/ 3	良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む） / 腫瘍疼痛/ WORSENING ABDOMINAL TUMOR PAIN#	RELATED/ SAE [H]/ N	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (12)/ [redacted]20[redacted]:13:00 (12)	[redacted]20[redacted]:10:55 (6)/ 1	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
[redacted] (7[redacted]/F/W/D)	[redacted]20[redacted] (2)/ [redacted]20[redacted]:11:01 (3)	[redacted]20[redacted]:11:00 (2)/ 2	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (6)/ [redacted]20[redacted] (6)	[redacted]20[redacted]:11:00 (6)/ 1	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L 3B.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (7[redacted]/F/W/D)	[redacted]20[redacted] (12)/ [redacted]20[redacted]:12:58 (14)	[redacted]20[redacted]:11:30 (5)/ 3	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (21)/ [redacted]20[redacted]:02:00 (21)	[redacted]20[redacted]:11:15 (7)/ 1	一般・全身障害および投与部位の状態/ 発熱/ FEVER#	NOT RELATED/ SAE [H]/ N	Grade 1/ DOSE NOT CHANGED	N/ RECOVERED/RESOLVED
	[redacted]20[redacted] (163)/ [redacted]20[redacted] (170)	[redacted]20[redacted]:10:26 (2)/ 8	感染症および寄生虫症/ 唾液腺炎/ SALIVARY GLAND INFECTION	NOT RELATED/ SAE [H]/ N	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (6[redacted]/M/W/D)	[redacted]20[redacted] (17)/ [redacted]20[redacted]:10:32 (21)	[redacted]20[redacted]:12:06 (2)/ 5	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L 3B.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (6[redacted]/M/W/D)	/ [redacted] (64)	[redacted]:16:11	感染症および寄生虫症/ 気道感染/ RESPIRATORY INFECTION#	NOT RELATED/ SAE [H]/ N	Grade 3 (2)/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
		[redacted]:16:03	良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）/ 肺新生物/ LUNG NEOPLASM	NOT RELATED/ SAE [O]/ N	Grade 3/ DRUG WITHDRAWN	N/ RECOVERING/ RESOLVING
	/ [redacted] (96)	[redacted]:16:03	呼吸器、胸郭および縦隔障害/ 呼吸不全/ HYPOXEMIC RESPIRATORY FAILURE	NOT RELATED/ SAE [H]/ N	Grade 3/ NOT APPLICABLE	Y/ RECOVERED/RESOLVED
[redacted] (7[redacted]/M/W/D)	/ [redacted] (12)	[redacted]:18:22	感染症および寄生虫症/ 敗血症性ショック/ SEPTIC SHOCK#	NOT RELATED/ SAE [L, H]/ N	Grade 4/ DOSE DELAYED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L 3B.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (7[redacted]/M/W/D)	/ [redacted]20[redacted] (21)	[redacted]20[redacted]:20:07	肝胆道系障害/ 肝毒性/ HEPATHOTOXICITY#	NOT RELATED/ SAE [F, H]/ N	Grade 5 (3)/ NOT APPLICABLE	Y/ FATAL
[redacted] (3[redacted]/F/W/P)	[redacted]20[redacted] (21)/ [redacted]20[redacted] (26)	[redacted]20[redacted]:10:25 (7)/ 6	感染症および寄生虫症/ 菌血症/ BACTEREMIA#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (62)/ [redacted]20[redacted] (68)	[redacted]20[redacted]:10:40 (1)/ 7	感染症および寄生虫症/ 菌血症/ BACTEREMIA	NOT RELATED/ SAE [H]/ N	Grade 2/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
[redacted] (4[redacted]/M/W/D)	/ [redacted]20[redacted] (25)	[redacted]20[redacted]:13:05	一般・全身障害および投与部位の状態/ 発熱/ NON-NEUTROPENIC FEVER#	NOT RELATED/ SAE [H]/ N	Grade 2/ DOSE DELAYED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L 3B.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (8[redacted]/F/W/D)	/ [redacted] (16)	[redacted]:17:15	胃腸障害/ 嘔吐/ VOMITING#	NOT RELATED/ SAE [H]/ N	Grade 2/ DOSE NOT CHANGED	N/ RECOVERED/RESOLVED
	/ [redacted] (22)	[redacted]:17:15	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	/ [redacted] (17)	[redacted]:17:15	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 3 (2)/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (6[redacted]/M/W/D)	/ [redacted] (10)	[redacted]:12:30	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L 3B.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (6[redacted]/M/W/D)		[redacted]:18:40	良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む） / 腫瘍フレア/ TUMOR FLARE#	RELATED/ SAE [H]/ N	Grade 2/ DOSE NOT CHANGED	N/ RECOVERING/ RESOLVING
	/ [redacted] (35)	[redacted]:14:54	胃腸障害/ 小腸出血/ ILEAL HEMORRHAGE SECONDARY TO ILEAL FISTULA#	NOT RELATED/ SAE [H]/ N	Grade 2/ DOSE NOT CHANGED	U/ RECOVERED/RESOLVED
	[redacted] (30)	[redacted]:11:10 (2)	胃腸障害/ 腸管穿孔/ INTESTINAL PERFORATION#	NOT RELATED/ SAE [H]/ N	Grade 2/ DOSE NOT CHANGED	Y/ NOT RECOVERED/NOT RESOLVED
	/ [redacted] (16)	[redacted]:18:40	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L 3B.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (5[redacted]/F/W/D)	[redacted] (323)/ [redacted] :19:05 (400)	[redacted] :17:11 (1)/ 78	神経系障害/ 水頭症/ WORSENING OF CHRONIC HYDROCEPHALUS	NOT RELATED/ SAE [D, O]/ N	Grade 3/ DOSE DELAYED	N/ RECOVERED/RESOLVED
	[redacted] (379)/ [redacted] (382)	[redacted] :16:15 (20)/ 4	神経系障害/ 水頭症/ HOSPITALIZATION DUE TO WORSENING OF CHRONIC HYDROCEPHALUS	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted] (56)/ [redacted] :11:54 (56)	[redacted] :15:48 (49)/ 1	血液およびリンパ系障害/ リンパ球減少症/ LYMPHOPENIA#	NOT RELATED/ SAE [O]/ N	Grade 3/ DOSE NOT CHANGED	N/ RECOVERED/RESOLVED
	/ [redacted] (21)	[redacted] :14:56	血管障害/ 低血圧/ HYPOTENSION#	RELATED/ SAE [H]/ N	Grade 1/ DOSE NOT CHANGED	N/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L 3B.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (5[redacted]/F/W/D)	/ [redacted]20[redacted]:23:00 (22)	[redacted]20[redacted]:14:56	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	/ [redacted]20[redacted]:22:12 (29)	[redacted]20[redacted]:17:15	血管障害/ 低血圧/ HYPOTENSION#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	N/ RECOVERED/RESOLVED
	[redacted]20[redacted] (184)/ [redacted]20[redacted]:15:36 (188)	[redacted]20[redacted]:15:13 (16)/ 5	血液およびリンパ系障害/ 発熱性好中球減少症/ FEBRILE NEUTROPENIA	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (281)/ [redacted]20[redacted]:11:00 (323)	[redacted]20[redacted]:14:53 (29)/ 43	血液およびリンパ系障害/ 好中球減少症/ NEUTROPENIA	NOT RELATED/ SAE [O]/ N	Grade 3/ DOSE NOT CHANGED	N/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L 3B.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (5[redacted]/F/W/D)	[redacted]20[redacted] (389)/ [redacted]20[redacted] (391)	[redacted]20[redacted]:16:15 (30)/ 3	神経系障害/ 水頭症/ HOSPITALIZATION DUE TO WORSENING OF CHRONIC HYDROCEPHALUS (DEFINITIVE NEUROSURGERY)	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
[redacted] (5[redacted]/F/W/D)	/[redacted]20[redacted] (7)	[redacted]20[redacted]:18:12	感染症および寄生虫症/ 敗血症性ショック/ SEPTIC SHOCK#	NOT RELATED/ SAE [L, H, O]/ N	Grade 4/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (5)/ [redacted]20[redacted] (23)	[redacted]20[redacted]:18:12 (5)/ 19	代謝および栄養障害/ 低カリウム血症/ INTERMITTENT HYPOKALEMIA#	NOT RELATED/ SAE [O]/ N	Grade 3/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	/[redacted]20[redacted] (20)	[redacted]20[redacted]:18:12	感染症および寄生虫症/ 菌血症/ BACTEREMIA#	NOT RELATED/ SAE [H]/ N	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L 3B.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (5[redacted]/F/W/D)	[redacted]20[redacted] (1)/ [redacted]20[redacted]:08:00 (28)	/ 28	血液およびリンパ系障害/ 白血球減少症/ LUEKOPENIA WORSENING*	NOT RELATED/ SAE [O]/ N	Grade 4 (3)/ DOSE NOT CHANGED	N/ RECOVERED/RESOLVED
		[redacted]20[redacted]:19:22	神経系障害/ 脊髄圧迫/ MEDULAR COMPRESSION T6-T11#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	Y/ NOT RECOVERED/NOT RESOLVED
	[redacted]20[redacted] (11)	[redacted]20[redacted]:19:22 (3)	傷害、中毒および処置合併症/脊髄ショック/SPINAL MEDULAR SHOCK DUE TO DISEASE PROGRESSION#	NOT RELATED/ SAE [H, D, O]/ N	Grade 3/ DOSE NOT CHANGED	Y/ NOT RECOVERED/NOT RESOLVED
	/ [redacted]20[redacted]:19:00 (16)	[redacted]20[redacted]:19:00	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 3/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L 3B.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (6[redacted]/M/N/D)	[redacted]20[redacted] (20)/ [redacted]20[redacted] (34)	[redacted]20[redacted]:15:45 (6)/ 15	感染症および寄生虫症/ ＣＯＶＩＤ－１９/ COVID 19 INFECTION#	NOT RELATED/ SAE [F, H]/ N	Grade 5 (3)/ DRUG WITHDRAWN	Y/ FATAL
	[redacted]20[redacted] (1)/ [redacted]20[redacted] (2)	[redacted]20[redacted]:16:30 (1)/ 2	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (9)/ [redacted]20[redacted] (14)	[redacted]20[redacted]:14:30 (2)/ 6	呼吸器、胸郭および縦隔障害/ 胸水/ PLEURAL EFFUSION#	RELATED/ SAE [H]/ N	Grade 4 (3)/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (5[redacted]/M/N/D)	[redacted]20[redacted] (15)/ [redacted]20[redacted] (137)	[redacted]20[redacted]:15:15 (8)/ 123	感染症および寄生虫症/ 進行性多巣性白質脳症/ PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY#	NOT RELATED/ SAE [F, H]/ N	Grade 5 (2)/ DRUG WITHDRAWN	N/ FATAL

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L 3B.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (5[redacted]/F/N/D)	[redacted]20[redacted] (17)/ [redacted]20[redacted] (17)	[redacted]20[redacted]:15:32 (3)/ 1	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	N/ RECOVERED/RESOLVED
[redacted] (5[redacted]/M/N/D)	[redacted]20[redacted] (49)	[redacted]20[redacted]:14:40 (42)	筋骨格系および結合組織障害/ 関節痛/ RIGHT HIP PAIN#	NOT RELATED/ SAE [H]/ N	Grade 3 (1)/ DOSE NOT CHANGED	Y/ NOT RECOVERED/NOT RESOLVED
	[redacted]20[redacted] (51)/ [redacted]20[redacted] (56)	[redacted]20[redacted]:11:45 (1)/ 6	傷害、中毒および処置合併症/ 大腿骨頸部骨折/ FRACTURE OF THE RIGHT FEMORAL NECK#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	N/ RECOVERED/RESOLVED
	[redacted]20[redacted] (86)	[redacted]20[redacted]:11:45 (36)	感染症および寄生虫症/ ＣＯＶＩＤ－１９/ COVID 19 INFECTION#	NOT RELATED/ SAE [H]/ N	Grade 3 (2)/ DRUG WITHDRAWN	Y/ NOT RECOVERED/NOT RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L 3B.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (6[redacted]/F/N/D)	[redacted]20[redacted] (18)/ [redacted]20[redacted] (20)	[redacted]20[redacted]:16:00 (4)/ 3	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (7[redacted]/F/N/D)	[redacted]20[redacted] (8)/ [redacted]20[redacted]:16:00 (15)	[redacted]20[redacted]:16:20 (2)/ 8	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (25)	[redacted]20[redacted]:16:05 (4)	神経系障害/ 急性多発ニューロパチー/ ACUTE POLYRADICULONEURITIS#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE DELAYED	Y/ NOT RECOVERED/NOT RESOLVED
[redacted] (6[redacted]/F/N/D)	[redacted]20[redacted] (19)/ [redacted]20[redacted]:22:00 (21)	[redacted]20[redacted]:14:00 (4)/ 3	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L 3B.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (7[redacted]/F/N/D)	[redacted]20[redacted] (17)/ [redacted]20[redacted]:19:56 (20)	[redacted]20[redacted]:12:05 (3)/ 4	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2 (1)/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (7[redacted]/M/N/D)	[redacted]20[redacted] (353)/ [redacted]20[redacted] (364)	[redacted]20[redacted]:11:20 (57)/ 12	傷害、中毒および処置合併症/ 硬膜下血腫/ SUBDURAL HEMATOMA	NOT RELATED/ SAE [H]/ N	Grade 4 (3)/ DOSE NOT CHANGED	N/ RECOVERED/RESOLVED
	[redacted]20[redacted] (7)/ [redacted]20[redacted]:23:00 (8)	[redacted]20[redacted]:15:15 (7)/ 2	血液およびリンパ系障害/ 発熱性好中球減少症/ FEBRILE NEUTROPENIA#	NOT RELATED/ SAE [H]/ N	Grade 4/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (6[redacted]/F/N/D)	[redacted]20[redacted] (16)/ [redacted]20[redacted]:08:00 (22)	[redacted]20[redacted]:17:49 (2)/ 7	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L 3B.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (4[redacted]/M/W/D)	[redacted]20[redacted] (50)/ [redacted]20[redacted] (57)	[redacted]20[redacted]:11:17 (8)/ 8	感染症および寄生虫症/ シュードモナス性尿路感染/ PSEUDOMONAS AERUGINOSA URINARY INFECTION#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (60)/ [redacted]20[redacted] (69)	[redacted]20[redacted]:11:17 (18)/ 10	感染症および寄生虫症/ 細菌性腎盂腎炎/ RIGHT PYELONEPHRITIS FROM PSEUDOMONAS AERUGINOSA	NOT RELATED/ SAE [H]/ N	Grade 2/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (150)/ [redacted]20[redacted] (158)	[redacted]20[redacted]:12:33 (39)/ 9	感染症および寄生虫症/ 尿路性敗血症/ URINARY SEPSIS$	NOT RELATED/ SAE [H]/ N	Grade 3/ NOT APPLICABLE	Y/ RECOVERED/RESOLVED
[redacted] (4[redacted]/M/W/D)	[redacted]20[redacted] (7)	[redacted]20[redacted]:12:20 (7)	血液およびリンパ系障害/ 血小板減少症/ WORSENING THROMBOCYTOPENIA#	RELATED/ SAE [L, H]/ N	Grade 4/ DOSE DELAYED	Y/ NOT RECOVERED/NOT RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L 3B.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (4[redacted]/F/A/D)	[redacted] (25)/ [redacted] :08:33 (29)	[redacted] :11:57 (4)/ 5	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (4[redacted]/M/A/D)	[redacted] (27)	[redacted] :10:50 (5)	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2/ DOSE DELAYED	Y/ NOT RECOVERED/NOT RESOLVED
[redacted] (5[redacted]/M/A/D)	[redacted] (293)/ [redacted] (294)	[redacted] :12:19 (11)/ 2	血管障害/ 血腫/ HEMATOMA	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted] (296)/ [redacted] (304)	[redacted] :12:19 (14)/ 9	感染症および寄生虫症/ 肺炎/ PNEUMONIA	NOT RELATED/ SAE [H]/ N	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L 3B.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (4[redacted]/M/A/H)	[redacted]20[redacted] (382)	[redacted]20[redacted]:12:00 (17)	感染症および寄生虫症/ ＣＯＶＩＤ－１９肺炎/ COVID19 PNEUMONIA	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	Y/ RECOVERING/ RESOLVING
[redacted] (6[redacted]/F/A/D)	[redacted]20[redacted] (101)	[redacted]20[redacted]:12:31 (16)	筋骨格系および結合組織障害/ 四肢痛/ RIGHT ARM PAIN	NOT RELATED/ SAE [H]/ N	Grade 2 (1)/ DOSE DELAYED	Y/ NOT RECOVERED/NOT RESOLVED
	/ [redacted]20[redacted]:08:00 (18)	[redacted]20[redacted]:11:49	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (5[redacted]/F/A/D)	[redacted]20[redacted] (156)/ [redacted]20[redacted]:08:00 (165)	[redacted]20[redacted]:11:20 (16)/ 10	感染症および寄生虫症/ 帯状疱疹/ HERPES ZOSTER	NOT RELATED/ SAE [H]/ N	Grade 1/ DOSE DELAYED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L 3B.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (5[redacted]/F/A/D)	[redacted]20[redacted] (15)/ [redacted]20[redacted]:12:00 (19)	[redacted]20[redacted]:10:10 (1)/ 5	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 3 (1)/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
[redacted] (8[redacted]/M/A/D)	[redacted]20[redacted] (17)/ [redacted]20[redacted]:09:00 (17)	[redacted]20[redacted]:13:23 (3)/ 1	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (7[redacted]/F/A/D)	[redacted]20[redacted] (10)	[redacted]20[redacted]:10:43 (3)	胃腸障害/ 膵炎/ PANCREATITIS#	RELATED/ SAE [H]/ N	Grade 3/ DOSE DELAYED	Y/ NOT RECOVERED/NOT RESOLVED
	[redacted]20[redacted] (17)/ [redacted]20[redacted]:05:26 (25)	[redacted]20[redacted]:10:43 (10)/ 9	神経系障害/ 免疫エフェクター細胞関連神経毒性症候群/ IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME(ICANS)#	RELATED/ SAE [F, H]/ Y	Grade 5 (1)/ DRUG WITHDRAWN	Y/ FATAL

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L 3B.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (7[redacted]/F/A/D)	[redacted] (17)	[redacted]:10:43 (10)	神経系障害/ 脳虚血/ ISCHEMIA CEREBROVASCULAR#	NOT RELATED/ SAE [H]/ N	Grade 1/ DOSE NOT CHANGED	Y/ NOT RECOVERED/NOT RESOLVED
[redacted] (6[redacted]/M/W/D)	/ [redacted] (21)	[redacted]:14:36	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (7[redacted]/M/W/D)	/ [redacted] (16)	[redacted]:12:36	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	N/ RECOVERED/RESOLVED
[redacted] (4[redacted]/M/W/D)	[redacted] (121)/ [redacted] (127)	[redacted]:14:00 (8)/ 7	感染症および寄生虫症/ 蜂巣炎/ SKIN INFECTION (CELLULITIS)	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L 3B.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (4[redacted]/M/W/D)	/ [redacted] (17)	[redacted]:15:33	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	/ [redacted]:16:45 (22)	[redacted]:15:33	感染症および寄生虫症/ 肺炎/ INFECTION LUNG#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	/ [redacted]:08:17 (22)	[redacted]:15:33	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (2[redacted]/M/W/D)	[redacted] (6)/ [redacted] (9)	[redacted]:11:32 (6)/ 4	胃腸障害/ 十二指腸穿孔/ SMALL DUODENAL PERFORATION#	NOT RELATED/ SAE [H]/ N	Grade 2/ DOSE DELAYED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L 3B.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (2[redacted]/M/W/D)	[redacted]20[redacted] (14)/ [redacted]20[redacted] (22)	[redacted]20[redacted]:11:32 (14)/ 9	胃腸障害/ 上腹部痛/ STOMACH PAIN#	NOT RELATED/ SAE [H]/ N	Grade 2/ DOSE NOT CHANGED	N/ RECOVERED/RESOLVED
[redacted] (5[redacted]/M/W/D)	[redacted]20[redacted] (2)/ [redacted]20[redacted]:15:00 (3)	[redacted]20[redacted]:15:30 (2)/ 2	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	N/ RECOVERED/RESOLVED
	[redacted]20[redacted] (20)/ [redacted]20[redacted] (20)	[redacted]20[redacted]:12:45 (6)/ 1	神経系障害/ 免疫エフェクター細胞関連神経毒性症候群/ ICANS#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	N/ RECOVERED/RESOLVED
	[redacted]20[redacted] (20)/ [redacted]20[redacted]:19:00 (20)	[redacted]20[redacted]:12:45 (6)/ 1	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	N/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L 3B.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (3[redacted]/F/W/H)	[redacted]20[redacted] (13)/ [redacted]20[redacted] (14)	[redacted]20[redacted]:12:08 (6)/ 2	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (27)/ [redacted]20[redacted] (28)	[redacted]20[redacted]:12:20 (6)/ 2	心臓障害/ 心タンポナーデ/ PERICARDIAL TAMPONADE#	NOT RELATED/ SAE [H]/ N	Grade 4/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (32)	[redacted]20[redacted]:14:02 (2)	呼吸器、胸郭および縦隔障害/ 胸水/ PLEURAL EFFUSION#	NOT RELATED/ SAE [H]/ N	Grade 2/ DRUG WITHDRAWN	Y/ NOT RECOVERED/NOT RESOLVED
	[redacted]20[redacted] (16)/ [redacted]20[redacted]:09:00 (16)	[redacted]20[redacted]:12:53 (2)/ 1	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2 (1)/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L 3B.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (6[redacted]/M/W/D)	[redacted]20[redacted] (32)/ [redacted]20[redacted] (32)	[redacted]20[redacted]:11:35 (4)/ 1	一般・全身障害および投与部位の状態/全身健康状態悪化/ SIGNS/SYMPTOMS OF CLINICAL PROGRESSION THAT WAS FATAL (GENERAL PHYSIXAL HEALTH DETORIATION)#	NOT RELATED/ SAE [F, L]/ N	Grade 5/ DRUG WITHDRAWN	N/ FATAL
		[redacted]20[redacted]:16:10	一般・全身障害および投与部位の状態/ 倦怠感/ MALAISE#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	N/ NOT RECOVERED/NOT RESOLVED
[redacted] (5[redacted]/M/W/D)	[redacted]20[redacted] (74)/ [redacted]20[redacted]:14:00 (85)	[redacted]20[redacted]:12:20 (11)/ 12	心臓障害/ 心嚢液貯留/ PERICARDIAL EFFUSION	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (91)/ [redacted]20[redacted]:11:00 (94)	[redacted]20[redacted]:13:30 (7)/ 4	呼吸器、胸郭および縦隔障害/ 胸水/ PLEURAL EFFUSION	NOT RELATED/ SAE [H]/ N	Grade 3/ NOT APPLICABLE	U/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L 3B.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (5[redacted]/M/W/D)	[redacted]20[redacted] (115)	[redacted]20[redacted]:13:30 (31)	呼吸器、胸郭および縦隔障害/ 呼吸困難/ DYSPNEA	NOT RELATED/ SAE [H]/ N	Grade 3/ NOT APPLICABLE	N/ NOT RECOVERED/NOT RESOLVED
	[redacted]20[redacted] (119)/ [redacted]20[redacted]:13:45 (119)	[redacted]20[redacted]:13:30 (35)/ 1	神経系障害/ 意識消失/ NEUROLOGICAL DECLINE (LOST OF CONSCIOUSNESS)	NOT RELATED/ SAE [F, H]/ N	Grade 5/ NOT APPLICABLE	N/ FATAL
[redacted] (7[redacted]/M/W/D)	[redacted]20[redacted] (33)/ [redacted]20[redacted]:10:00 (57)	[redacted]20[redacted]:15:25 (5)/ 25	良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）/ 感染性新生物/ INFECTION AT LYMPHOMA LESION HIP#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (6[redacted]/F/W/D)	[redacted]20[redacted] (17)/ [redacted]20[redacted] (18)	[redacted]20[redacted]:14:30 (3)/ 2	血液およびリンパ系障害/ 貧血/ ANEMIA#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L 3B.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (7[redacted]/F/W/D)	[redacted] 20[redacted] (42)	[redacted] 20[redacted]:12:34 (7)	血管障害/ 血栓性静脈炎/ THTOMBOPHLEBITIS SUSPECTED#	NOT RELATED/ SAE [H]/ N	Grade 4/ DOSE DELAYED	Y/ RECOVERING/ RESOLVING
[redacted] (7[redacted]/M/W/D)	[redacted] 20[redacted] (100)/ [redacted] 20[redacted] (112) (23)/ 13	[redacted] 20[redacted]:14:59	一般・全身障害および投与部位の状態/ 末梢性浮腫/ LOWER LEG EDEMA	RELATED/ SAE [H]/ N	Grade 2/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
[redacted] (4[redacted]/M/W/D)	[redacted] 20[redacted] (23)/ [redacted] 20[redacted] (43) (9)/ 21	[redacted] 20[redacted]:14:00	感染症および寄生虫症/ 口腔ヘルペス/ HERPES LABIALIS, ULCERATIVE TYPE#	RELATED/ SAE [H]/ N	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted] 20[redacted] (44)/ [redacted] 20[redacted] (49) (16)/ 6	[redacted] 20[redacted]:14:25	感染症および寄生虫症/ 上気道感染/ UPPER RESPIRATORY TRACTS INFECTION#	RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L 3B.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (6[redacted]/F/A/D)	[redacted]20[redacted] (6)/ [redacted]20[redacted] (35)	[redacted]20[redacted]:18:34 (6)/ 30	血液およびリンパ系障害/ リンパ節症/ INCREASING LYMPHADENOPATHY.#	RELATED/ SAE [H]/ N	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (6)/ [redacted]20[redacted] (37)	[redacted]20[redacted]:16:10 (-8)/ 32	感染症および寄生虫症/ 敗血症/ SEPSIS#	RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (7[redacted]/M/A/D)	[redacted]20[redacted] (56)/ [redacted]20[redacted] (58)	[redacted]20[redacted]:14:39 (7)/ 3	一般・全身障害および投与部位の状態/ 発熱/ FEVER#	NOT RELATED/ SAE [H]/ N	Grade 1/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
[redacted] (6[redacted]/F/A/D)	[redacted]20[redacted] (17)/ [redacted]20[redacted] (22)	[redacted]20[redacted]:14:39 (3)/ 6	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L 3B.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (6[redacted]/F/A/D)	[redacted] (26)/ [redacted] (28)	[redacted]:14:57 (5)/ 3	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (3[redacted]/M/A/D)	[redacted] (20)/ [redacted] (29)	[redacted]:14:22 (6)/ 10	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
[redacted] (5[redacted]/M/W/D)	/ [redacted] (22)	[redacted]:14:39	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
	/ [redacted] (79)	[redacted]:14:39	感染症および寄生虫症/ ＣＯＶＩＤ－１９/ COVID－１９#	NOT RELATED/ SAE [F, L, H]/ N	Grade 5 (3)/ DOSE DELAYED	Y/ FATAL

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L 3B.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (4[redacted]/M/W/D)	[redacted] (13)/ [redacted] :08:23 (20) / [redacted] (20)	[redacted] :16:56 (6)/ 8	腎および尿路障害/ 急性腎障害/ ACUTE KIDNEY INJURY#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
[redacted] (7[redacted]/M/W/D)	[redacted] (20)	[redacted] :10:05	感染症および寄生虫症/ 蜂巣炎/ CELLULITIS LEFT FOOT#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
	[redacted] (510)/ [redacted] (510) (259)/ 1	[redacted] :11:05	良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）/基底細胞癌/BASAL CELL CARCINOMA LESION LEFT CHEEK	NOT RELATED/ SAE [O]/ N	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted] (510)/ [redacted] (510) (77)/ 1	[redacted] :13:15	良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）/基底細胞癌/BASAL CELL CARCINOMA RIGHT CHEEK	NOT RELATED/ SAE [O]/ N	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L 3B.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (7[redacted]/M/N/D)	/ [redacted]20[redacted] (55)	[redacted]20[redacted]:12:00	筋骨格系および結合組織障害/ 瘻孔/ SPLENIC FISTULA#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (6[redacted]/M/W/D)	[redacted]20[redacted] (16)/ [redacted]20[redacted] (17)	[redacted]20[redacted]:12:40 (2)/ 2	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (20)/ [redacted]20[redacted] (30)	[redacted]20[redacted]:12:40 (6)/ 11	感染症および寄生虫症/ 腎盂腎炎/ PYELONEPHRITIS#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (51)	[redacted]20[redacted]:16:10 (23)	良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）/ 骨髄異形成症候群/ MYELODYSPLASTIC SYNDROME NOS#	NOT RELATED/ SAE [O]/ N	Grade 4/ DRUG WITHDRAWN	N/ NOT RECOVERED/NOT RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L 3B.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (6[redacted]/M/W/D)	[redacted]20[redacted] (56)/ [redacted]20[redacted] (60)	[redacted]20[redacted]:16:10 (28)/ 5	感染症および寄生虫症/ 敗血症/ SEPSIS#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
[redacted] (7[redacted]/F/W/D)	[redacted]20[redacted] (16)/ [redacted]20[redacted]:20:05 (24)	[redacted]20[redacted]:14:30 (2)/ 9	神経系障害/ 免疫エフェクター細胞関連神経毒性症候群/ ICANS#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (8[redacted]/F/W/D)	[redacted]20[redacted] (21)/ [redacted]20[redacted]:18:38 (22)	[redacted]20[redacted]:10:12 (7)/ 2	神経系障害/ 一過性脳虚血発作/ TRANSIENT ISCHEMIC ATTACK#	NOT RELATED/ SAE [H]/ N	Grade 1/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
[redacted] (6[redacted]/M/W/D)	[redacted]20[redacted] (10)/ [redacted]20[redacted] (10)	[redacted]20[redacted]:11:11 (3)/ 1	心臓障害/ 心筋梗塞/ MYOCARDIAL INFARCTION#	NOT RELATED/ SAE [F, L, H, D]/ N	Grade 5/ NOT APPLICABLE	Y/ FATAL

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L 3B.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (4[redacted]/F/O/D)	[redacted]20[redacted] (16)/ [redacted]20[redacted] (17)	[redacted]20[redacted]:10:59 (2)/ 2	良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む） / 腫瘍疼痛/ TUMOR PAIN#	RELATED/ SAE [H]/ N	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (6[redacted]/F/W/D)	[redacted]20[redacted] (404)/ [redacted]20[redacted]:18:22 (407)	[redacted]20[redacted]:12:56 (40)/ 4	呼吸器、胸郭および縦隔障害/ 呼吸困難/ DYSPNEA	NOT RELATED/ SAE [H]/ N	Grade 3/ NOT APPLICABLE	Y/ RECOVERED/RESOLVED
[redacted] (7[redacted]/M/W/D)	[redacted]20[redacted] (40)/ [redacted]20[redacted] (40)	[redacted]20[redacted]:11:37 (5)/ 1	一般・全身障害および投与部位の状態/ 非心臓性胸痛/ CHEST PAIN- NONCARDIAC#	NOT RELATED/ SAE [H]/ N	Grade 1/ DOSE NOT CHANGED	N/ RECOVERED/RESOLVED
[redacted] (6[redacted]/F/W/D)	[redacted]20[redacted] (183)	[redacted]20[redacted]:10:56 (7)	良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む） / 骨髄異形成症候群/ MYELODYSPLASTIC SYNDROME	NOT RELATED/ SAE [O]/ N	Grade 4/ DRUG WITHDRAWN	U/ NOT RECOVERED/NOT RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L 3B.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (6[redacted]/F/W/D)	[redacted] (2)/ [redacted] (4)	[redacted] :12:35 (2)/ 3	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (7[redacted]/F/W/D)	[redacted] (7)	[redacted] :13:39 (7)	臨床検査/ 血中乳酸脱水素酵素増加/ BLOOD LDH ELEVATED#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	Y/ NOT RECOVERED/NOT RESOLVED
/ [redacted] (8)		[redacted] :13:39	代謝および栄養障害/ 高カルシウム血症/ HYPERCALCEMIA#	NOT RELATED/ SAE [H]/ N	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (5[redacted]/M/W/D)	[redacted] (13)/ [redacted] (16)	[redacted] :15:18 (5)/ 4	精神障害/ 精神状態変化/ ALTERED MENTAL STATUS#	NOT RELATED/ SAE [H]/ N	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L 3B.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (5[redacted]/M/W/D)	[redacted] (72)/ [redacted] (75)	[redacted] :11:39 (1)/ 4	腎および尿路障害/ 急性腎障害/ ACUTE RENAL FAILURE	NOT RELATED/ SAE [H]/ N	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (6[redacted]/M/W/D)	[redacted] (31)	[redacted] :14:00 (17)	神経系障害/ 頭痛/ HEADACHE#	NOT RELATED/ SAE [H, O]/ N	Grade 3 (1)/ DOSE NOT CHANGED	Y/ NOT RECOVERED/NOT RESOLVED
[redacted] (4[redacted]/F/O/D)	[redacted] (17)/ [redacted] :17:11 (18)	[redacted] :10:00 (3)/ 2	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2 (1)/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted] (73)/ [redacted] (83)	[redacted] :16:35 (9)/ 11	筋骨格系および結合組織障害/ 腋窩腫瘤/ LEFT AXILLARY MASS INFECTION	NOT RELATED/ SAE [H]/ N	Grade 3/ NOT APPLICABLE	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L 3B.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (6[redacted]/F/W/D)	[redacted]20[redacted] (16)/ [redacted]20[redacted] (17)	[redacted]20[redacted]:11:11 (2)/ 2	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (7[redacted]/F/W/D)	[redacted]20[redacted] (18)/ [redacted]20[redacted]:17:30 (18)	[redacted]20[redacted]:15:32 (2)/ 1	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (5[redacted]/M/A/H)	[redacted]20[redacted] (14)/ [redacted]20[redacted]:18:39 (15)	[redacted]20[redacted]:11:44 (1)/ 2	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[D]LBCL, [H]GBCL, [P]MBCL, [F]L 3B.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (6[redacted]/M/W/F)	[redacted]20[redacted] (43)/ [redacted]20[redacted] (64)	[redacted]20[redacted]:11:25 (7)/ 22	感染症および寄生虫症/ニューモシスチス・イロベチイ肺炎/ PNEUMOCYSTIS JIROVECII PNEUMONIA (PJP)#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (21)/ [redacted]20[redacted] (21)	[redacted]20[redacted]:09:40 (6)/ 1	神経系障害/ 失神/ SYNCOPE#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
[redacted] (7[redacted]/M/W/F)	[redacted]20[redacted] (16)/ [redacted]20[redacted]:11:19 (17)	[redacted]20[redacted]:14:35 (8)/ 2	一般・全身障害および投与部位の状態/ 発熱/ FEVER#	NOT RELATED/ SAE [H]/ N	Grade 1/ DOSE NOT CHANGED	N/ RECOVERED/RESOLVED
	[redacted]20[redacted] (49)/ [redacted]20[redacted]:10:04 (52)	[redacted]20[redacted]:14:50 (5)/ 4	良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）/ 腫瘍熱/ TUMOR ASSOCIATED FEVER#	NOT RELATED/ SAE [H]/ N	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[F]L 1-3A, [M]ZL, [S]LL, [H]GBCL, [D]LBCL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (7[redacted]/F/W/F)	[redacted]20[redacted] (337)	[redacted]20[redacted]:13:00 (6)	良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）/ 肺扁平上皮癌/ LUNG SQUAMOUS CELL CARCINOMA	NOT RELATED/ SAE [O]/ N	Grade 3/ DOSE NOT CHANGED	Y/ NOT RECOVERED/NOT RESOLVED
	[redacted]20[redacted] (17)/ [redacted]20[redacted]:11:20 (18)	[redacted]20[redacted]:14:10 (2)/ 2	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (7[redacted]/F/W/M)	[redacted]20[redacted] (20)/ [redacted]20[redacted]:04:00 (22)	[redacted]20[redacted]:11:35 (5)/ 3	一般・全身障害および投与部位の状態/ 発熱/ NON-NEUTROPENIC FEVER#	NOT RELATED/ SAE [H]/ N	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (17)/ [redacted]20[redacted]:16:30 (17)	[redacted]20[redacted]:11:35 (2)/ 1	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[F]L 1-3A, [M]ZL, [S]LL, [H]GBCL, [D]LBCL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (8[redacted]/F/W/F)	[redacted]20[redacted] (2)/ [redacted]20[redacted] (5)	[redacted]20[redacted]:14:16 (2)/ 4	感染症および寄生虫症/ ウイルス性胃腸炎/ VIRAL GASTROENTERITIS#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	N/ RECOVERED/RESOLVED
	[redacted]20[redacted] (30)/ [redacted]20[redacted] (43)	[redacted]20[redacted]:14:30 (2)/ 14	肝胆道系障害/ 胆嚢炎/ CHOLECYSTITIS#	NOT RELATED/ SAE [H]/ N	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (9)/ [redacted]20[redacted] (10)	[redacted]20[redacted]:15:24 (2)/ 2	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (29)/ [redacted]20[redacted]:00:50 (30)	[redacted]20[redacted]:14:30 (1)/ 2	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[F]L 1-3A, [M]ZL, [S]LL, [H]GBCL, [D]LBCL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (8[redacted]/M/W/M)	[redacted]20[redacted] (16)/ [redacted]20[redacted]:20:00 (16)	[redacted]20[redacted]:09:33 (2)/ 1	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (5[redacted]/M/O/F)	[redacted]20[redacted] (19)/ [redacted]20[redacted] (21)	[redacted]20[redacted]:16:08 (12)/ 3	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2 (1)/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (54)/ [redacted]20[redacted] (57)	[redacted]20[redacted]:16:30 (5)/ 4	神経系障害/ 免疫エフェクター細胞関連神経毒性症候群/ IMMUNE EFFECTOR CELL ASSOCIATED NEUROTOXICITY SYNDROME#	RELATED/ SAE [H]/ Y	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (113) [redacted] (57)	[redacted]20[redacted]:14:25	免疫系障害/ 成人多臓器炎症症候群/ MULTISYSTEM INFLAMMATORY SYNDROME - ADULT	RELATED/ SAE [H, D]/ N	Grade 3/ NOT APPLICABLE	Y/ RECOVERING/ RESOLVING

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[F]L 1-3A, [M]ZL, [S]LL, [H]GBCL, [D]LBCL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (5[redacted]/M/O/F)	[redacted]20[redacted] (42)/ [redacted]20[redacted] (49)	[redacted]20[redacted]:14:03 (7)/ 8	感染症および寄生虫症/ 腸球菌性尿路感染/ ENTEROCOCCUS URINARY TRACT INFECTION#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (42)/ [redacted]20[redacted] (71)	[redacted]20[redacted]:14:03 (7)/ 30	呼吸器、胸郭および縦隔障害/ 肺塞栓症/ LEFT PULMONARY THROMBOEMBOLISM#	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (34)/ [redacted]20[redacted] (86)	[redacted]20[redacted]:14:25 (-22)/ 53	感染症および寄生虫症/ニューモシスチス・イロベチイ肺炎/ PNEUMOOCYSTIS JIROVECII PNEUMONIA	RELATED/ SAE [H]/ N	Grade 3/ DOSE DELAYED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (81)/ [redacted]20[redacted] (93)	[redacted]20[redacted]:14:25 (25)/ 13	感染症および寄生虫症/ ＣＯＶＩＤ－１９/ COVID－19 INFECTION	NOT RELATED/ SAE [H, O]/ N	Grade 3/ DOSE DELAYED	U/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[F]L 1-3A, [M]ZL, [S]LL, [H]GBCL, [D]LBCL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (5[redacted]/M/W/M)	[redacted] 20[redacted] (35)/ [redacted] 20[redacted] (36)	[redacted] 20[redacted]:10:30 (2)/ 2	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROM#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	N/ RECOVERED/RESOLVED
	[redacted] 20[redacted] (16)/ [redacted] 20[redacted]:16:30 (17)	[redacted] 20[redacted]:11:00 (2)/ 2	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROM#	RELATED/ SAE [H]/ Y	Grade 3/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (5[redacted]/F/W/F)	[redacted] 20[redacted] (4)/ [redacted] 20[redacted] (7)	[redacted] 20[redacted]:15:54 (4)/ 4	感染症および寄生虫症/ 肺炎/ PNEUMONIA#	NOT RELATED/ SAE [F, L, H, O]/ N	Grade 5 (3)/ DRUG WITHDRAWN	Y/ FATAL
[redacted] (7[redacted]/M/W/F)	[redacted] 20[redacted] (15)/ [redacted] 20[redacted] (17)	[redacted] 20[redacted]:14:15 (1)/ 3	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROM#	RELATED/ SAE [H]/ Y	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[F]L 1-3A, [M]ZL, [S]LL, [H]GBCL, [D]LBCL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.

Serious Adverse Events
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

Subject ID (Age/Sex/Race/Dx) [a]	Onset Date/Time Resolution Date/Time (Study Day)	Most Recent Dose Date/Time (Days since dose)/ Duration (Day)	System Organ Class/ Preferred Term/ Verbatim	Relationship/ Type [b]/ AESI	Toxicity Grade/ Action Taken	Treatment Required/ Outcome
[redacted] (7[redacted]/M/W/F)	[redacted]20[redacted] (23)/ [redacted]20[redacted]:18:59 (23)	[redacted]20[redacted]:12:20 (2)/ 1	神経系障害/ 免疫エフェクター細胞関連神経毒性症候群/ IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME#	RELATED/ SAE [H, O]/ Y	Grade 2/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (23)/ [redacted]20[redacted]:22:00 (23)	[redacted]20[redacted]:12:20 (2)/ 1	免疫系障害/ サイトカイン放出症候群/ CYTOKINE RELEASE SYNDROME#	RELATED/ SAE [H]/ Y	Grade 1/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
	[redacted]20[redacted] (167)/ [redacted]20[redacted]:09:46 (169)	[redacted]20[redacted]:10:40 (13)/ 3	代謝および栄養障害/ ２型糖尿病/ WORSENING OF EXACERBATION OF DIABETES MELLITUS TYPE II	NOT RELATED/ SAE [H]/ N	Grade 3/ DOSE NOT CHANGED	Y/ RECOVERED/RESOLVED
[redacted] (6[redacted]/F/O/F)	[redacted]20[redacted] (44)/ [redacted]20[redacted] (63)	[redacted]20[redacted]:14:50 (9)/ 20	良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）/ リンパ腫の転化/ NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL, CYST AND POLYPS) -- TRANSFORMATION FL IN DLBL --#	NOT RELATED/ SAE [F, O]/ N	Grade 5 (3)/ NOT APPLICABLE	Y/ FATAL

*=Pre-treatment event, $=post-treatment events, #=on-treatment events onset in Week <=8.
Note: Events are classified using MedDRA v24.1, and graded using CTCAE v5.0, ICANS as per Lee et al 2019, ASTCT grading for CRS as per Lee et al 2019, or CTLS as per Cairo-Bishop in Coiffier et al 2008.
Note: Initial toxicity grade displayed in the parenthesis for AEs with toxicity grade change.
[a] Age in years. Sex=[M]ale, [F]emale, or [U]ndifferentiated. Race= [W]hite, [B]lack or African American, [A]sian Indian/ Chinese/ Japanese/ Malay/ Asian Other, [O]ther/ American Indian or Alaska Native/ Native Hawaiian or Other Pacific Islander, [N]ot reported. Diagnosis at screening =[F]L 1-3A, [M]ZL, [S]LL, [H]GBCL, [D]LBCL.
[b] SAE criteria: [F]atal, [L]ife-threatening, Inpatient [H]ospitalization or prolongation of existing hospitalization, persistent or significant [D]isability/incapacity, [C]ongenital anomaly or birth defeat, and [O]ther.